Skip to main content
UniHealth

Doctor search

Rajesh Behl, MD

Hematology · Emeryville

NPI 1104844174

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
3
1 carrier
Office
1
Since medical school
33 years
Graduated 1993

Offices

1 location · Epic Care · 54 clinicians in this group

Looking this up.

Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · Contra Costa Regional Medical Center · John Muir Medical Center - Concord Campus · John Muir Medical Center - Walnut Creek Campus. That is not proof they admit you there this week.

Plans that list them

3 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Behl’s office at (510) 629-6682 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

Hospitals they work in

5 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
  • Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
  • Contra Costa Regional Medical CenterMartinez, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Contra Costa Health ServicesPatients rate it 3 of 5 · 73% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.167, Oct 2024 – Sep 2025
  • John Muir Medical Center - Concord CampusConcord, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.235, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.675, Oct 2024 – Sep 2025
  • John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend it
    Overall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Alta Bates Summit Medical Center
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths130.09 (87.72 to 172.46) · 109 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.274BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.227BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1 (0.06 to 1.94) · 1,209 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.88 (0.6 to 1.16)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.9 · 105 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.8 · 270 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths8.9 · 447 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths13.7 · 341 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths11.2 · 381 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.6 · 2,811 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.31) · 7,167 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.4) · 7,659 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.93 (0.92 to 4.94) · 1,668 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.25 (0 to 2.75) · 580 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.67 (1.19 to 4.15) · 1,446 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.17 (0.33 to 12.02) · 633 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths8.11 (4.67 to 11.55) · 619 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.15 to 3.07) · 309 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.39 (0 to 0.96) · 6,085 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.8 · 217 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.724No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.425No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.716No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits12.7 · 416 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.6 · 606 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-30.4 · 359 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-31.8 · 555 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-14.4 · 358 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16 · 382 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.1 (3.2 to 8.2) · 25 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.8 (7.3 to 16) · 25 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits4.5 · 232 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.9 · 56 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 152 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits14.8 (11.1 to 20) · 251 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.2 (0.9 to 1.5) · 579 casesNo differentJan 2024 – Dec 2024

What patients said (535 patients answered, 18% of those asked)

Patient survey stars by topic at Alta Bates Summit Medical Center
Cleanliness4
Nurse communication3
Doctor communication4
Communication about medicines2
Discharge information3
Overall hospital rating4
Quietness3
Recommend hospital5
Share of patients giving the best answer at Alta Bates Summit Medical Center
Room was "always" clean73%
Nurses "always" communicated well75%
Doctors "always" communicated well81%
Staff "always" explained58%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)75%
Staff "always" explained new medications73%
Nurses "always" explained things so they could understand69%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect85%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital78%
Staff "always" explained possible side effects43%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp

Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Alta Bates Summit Medical Center - Alta Bates Camp
Clostridium Difficile (C.Diff)Infections0.298BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.18 (0.16 to 2.2) · 730 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.87 (0.51 to 1.23)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths188.12 (132.31 to 243.94) · 50 casesNo differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths6.8 · 50 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.8 · 41 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.4 · 189 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths12.6 · 184 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 103 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.9 · 1,585 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.18 (0 to 0.4) · 3,929 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.31 (0.11 to 0.51) · 3,954 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.15 (0.95 to 5.36) · 754 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.62 (0 to 3.33) · 325 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.99 (0.39 to 3.59) · 717 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths10.85 (2.27 to 19.44) · 326 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.79 (1.08 to 8.49) · 302 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.68 (0.19 to 3.18) · 184 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.17 (0 to 0.88) · 3,240 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.4 · 161 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.207No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.48No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.785No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.4 · 243 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-58.2 · 194 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-12.3 · 177 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 209 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.4 (3.8 to 7.5) · 215 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.2 (9.4 to 15.5) · 215 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits4.8 · 150 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.2 · 81 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.4 (10 to 18.1) · 315 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.6 to 1.2) · 137 casesNo differentJan 2024 – Dec 2024

What patients said (449 patients answered, 15% of those asked)

Patient survey stars by topic at Alta Bates Summit Medical Center - Alta Bates Camp
Cleanliness2
Nurse communication2
Doctor communication2
Communication about medicines2
Discharge information2
Overall hospital rating2
Quietness2
Recommend hospital3
Share of patients giving the best answer at Alta Bates Summit Medical Center - Alta Bates Camp
Room was "always" clean62%
Nurses "always" communicated well72%
Doctors "always" communicated well75%
Staff "always" explained53%
Yes, staff "did" give patients this information82%
Yes, staff "did" give patients information about help after discharge82%
Doctors "always" explained things so they could understand68%
Doctors "always" listened carefully73%
Doctors "always" treated them with courtesy and respect83%
Patients who gave a rating of "9" or "10" (high)58%
Staff "always" explained new medications67%
Nurses "always" explained things so they could understand67%
Nurses "always" listened carefully66%
Nurses "always" treated them with courtesy and respect81%
"Always" quiet at night49%
"YES", patients would definitely recommend the hospital67%
Staff "always" explained possible side effects38%
Yes, staff "did" give patients information about possible symptoms83%
See every measure and the patient survey for Contra Costa Regional Medical Center

Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 1 better, 4 the same, 1 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Contra Costa Regional Medical Center
Clostridium Difficile (C.Diff)Infections0.167BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.99 (0 to 2.04) · 188 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.08 (0.63 to 1.53)No differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths7.2 · 44 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths8.8 · 111 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths16.4 · 114 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths12.3 · 27 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.7 · 321 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.2 (0 to 0.44) · 1,181 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.26 (0.05 to 0.47) · 1,198 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.2 (0.67 to 5.72) · 216 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.64 (0 to 3.36) · 71 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.5 (0.82 to 4.18) · 195 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths10.36 (1.01 to 19.71) · 72 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.88 (0.69 to 9.08) · 57 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.07 (0.55 to 3.58) · 67 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.93 (0 to 2.03) · 981 casesNo differentJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections1.948No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections2.027No differentOct 2024 – Sep 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.3 · 101 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits52.2 · 126 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-53.6 · 112 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 87 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (3.7 to 8.6) · 95 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.6 (8.8 to 17.8) · 95 casesNo differentJan 2024 – Dec 2024
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.2 · 35 casesNoneJul 2023 – Jun 2025

What patients said (521 patients answered, 10% of those asked)

Patient survey stars by topic at Contra Costa Regional Medical Center
Cleanliness4
Nurse communication3
Doctor communication3
Communication about medicines3
Discharge information3
Overall hospital rating4
Quietness2
Recommend hospital4
Share of patients giving the best answer at Contra Costa Regional Medical Center
Room was "always" clean79%
Nurses "always" communicated well76%
Doctors "always" communicated well80%
Staff "always" explained66%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge85%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)75%
Staff "always" explained new medications78%
Nurses "always" explained things so they could understand72%
Nurses "always" listened carefully73%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night45%
"YES", patients would definitely recommend the hospital73%
Staff "always" explained possible side effects54%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for John Muir Medical Center - Concord Campus

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at John Muir Medical Center - Concord Campus
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.235BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.675BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.11 (0.21 to 2) · 1,612 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.02 (0.77 to 1.28)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths184.13 (136.65 to 231.6) · 86 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.2 · 175 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.6 · 124 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.4 · 172 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths8 · 537 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths13.5 · 434 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths13 · 215 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.8 · 3,208 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.32 (0.13 to 0.51) · 7,626 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.23 (0.04 to 0.41) · 8,660 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.1 (1.29 to 4.91) · 2,723 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.21 (0 to 2.51) · 1,208 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths3 (1.7 to 4.3) · 2,355 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.77 (3.24 to 12.3) · 1,216 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths3.43 (0.43 to 6.43) · 1,253 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.93 (0.47 to 3.4) · 388 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths1.14 (0.58 to 1.69) · 6,288 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.1 · 263 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.636No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.254No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.904No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.5 · 312 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.1 · 768 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-6.8 · 295 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-3.1 · 648 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits31.1 · 433 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.1 · 504 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.7 (5.1 to 8.8) · 476 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.9 (10.5 to 15.7) · 476 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6.1 · 250 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits8.8 · 154 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits21.7 · 186 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.4 (9.9 to 17.9) · 192 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.7 to 1.2) · 546 casesNo differentJan 2024 – Dec 2024

What patients said (521 patients answered, 23% of those asked)

Patient survey stars by topic at John Muir Medical Center - Concord Campus
Cleanliness4
Nurse communication3
Doctor communication3
Communication about medicines2
Discharge information3
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at John Muir Medical Center - Concord Campus
Room was "always" clean72%
Nurses "always" communicated well78%
Doctors "always" communicated well80%
Staff "always" explained57%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)72%
Staff "always" explained new medications70%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully73%
Nurses "always" treated them with courtesy and respect83%
"Always" quiet at night46%
"YES", patients would definitely recommend the hospital77%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms84%
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus

Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at John Muir Medical Center - Walnut Creek Campus
Abdominopelvic accidental puncture or laceration rateComplications and deaths2.01 (1.17 to 2.85) · 2,206 casesWorseJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths222.42 (177.82 to 267.02) · 120 casesWorseJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths1.4 (0.91 to 1.9) · 9,764 casesWorseJul 2022 – Jun 2024
SSI - Colon SurgeryInfections2.734WorseOct 2024 – Sep 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.536BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.341BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.455BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.245BetterOct 2024 – Sep 2025
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.14 (0.87 to 1.4)No differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths6.4 · 131 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10 · 148 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.8 · 695 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths12.5 · 827 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths14.1 · 509 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.4 · 4,483 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.35 (0.18 to 0.53) · 11,630 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.05 to 0.39) · 11,793 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.33 (1.69 to 4.96) · 3,268 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.37 (0 to 2.94) · 1,631 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.76 (1.43 to 4.09) · 3,066 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.12 (0.22 to 12.02) · 1,580 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.43 (1.21 to 7.64) · 1,594 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.82 (0.4 to 3.24) · 685 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.9 · 615 casesNoneApr 2023 – Mar 2025
SSI - Abdominal HysterectomyInfections1.88No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.7 · 93 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.9 · 729 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-30.1 · 91 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-13 · 736 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits34.8 · 842 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.7 · 818 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.3 (3.3 to 8.4) · 28 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.8 (7.2 to 15.5) · 28 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits4.9 · 584 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.4 · 139 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.2 (9.9 to 17.9) · 222 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.1 (0.8 to 1.5) · 321 casesNo differentJan 2024 – Dec 2024

What patients said (758 patients answered, 24% of those asked)

Patient survey stars by topic at John Muir Medical Center - Walnut Creek Campus
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines2
Discharge information4
Overall hospital rating3
Quietness3
Recommend hospital4
Share of patients giving the best answer at John Muir Medical Center - Walnut Creek Campus
Room was "always" clean65%
Nurses "always" communicated well75%
Doctors "always" communicated well76%
Staff "always" explained55%
Yes, staff "did" give patients this information87%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand70%
Doctors "always" listened carefully75%
Doctors "always" treated them with courtesy and respect82%
Patients who gave a rating of "9" or "10" (high)69%
Staff "always" explained new medications68%
Nurses "always" explained things so they could understand71%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect83%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital77%
Staff "always" explained possible side effects42%
Yes, staff "did" give patients information about possible symptoms87%

Original Medicare doctor bills

$224,422

Medicare paid this office $224,422 for 537 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)420$90,938$78
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes67$47,822$105
Long return visit (40+ min)119$39,759$121
Short return visit (20+ min)105$9,648$55
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's224$9,315$15
See all 10 services
Every Original Medicare service billed
Return visit (30+ min)420$90,938$78
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes67$47,822$105
Long return visit (40+ min)119$39,759$121
Short return visit (20+ min)105$9,648$55
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's224$9,315$15
Initial hospital care with moderate level of medical decision making at least 75 minutes41$7,820$150
New patient visit (60+ min)33$4,600$139
Mechanical separation of red blood cells from blood11$3,727$89
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes22$3,361$70
Biopsy of bone marrow35$2,608$64

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Biopsy of bone marrow817572627341
Mechanical separation of red blood cells from blood––51–4042
Biopsy and aspiration of bone marrow sample for diagnosis–––1315–

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

537 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 20% · Women 48% · Also on Medicaid 21% · Health risk score 2.23. At or below the middle of the specialty; the typical hematology clinician is at 2.35.

Conditions among them: High blood pressure 68% · Chronic kidney disease 37% · Diabetes 30% · Coronary heart disease 23% · Cancer 21% · Atrial fibrillation 21% · Heart failure 18% · Depression 18% · COPD 11% · Stroke 10% · Dementia 8%.

The office billed $1,034,225, Medicare allowed $300,552 and paid $224,422; for 3,020 services of 23 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20245373,020762.23$1,034,225$224,422
20235812,969762.07$1,168,974$271,199
20225773,072762.07$1,175,671$270,994
20216153,134752.17$1,221,799$271,011
20206213,398752.28$1,447,368$255,637
20196343,356752.25$1,267,212$237,910
20186113,549742.33$1,458,993$256,762
20175473,046742.33$1,197,250$219,989
20164602,575732.21$1,012,290$177,810
20154342,342732.09$830,462$164,324
20143672,024732.11$697,587$130,636
20133261,864732.08$635,318$125,895

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 12 services

Original Medicare services billed in 2023
Return visit (30+ min)404$103,414$82
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes86$65,066$108
Long return visit (40+ min)146$43,463$124
Short return visit (20+ min)212$18,396$53
Initial hospital care with moderate level of medical decision making at least 75 minutes54$11,511$158
New patient visit (45+ min)48$5,546$116
New patient visit (60+ min)33$5,065$153
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes29$4,935$73
Mechanical separation of red blood cells from blood13$3,726$93
Biopsy of bone marrow52$3,556$59
Biopsy and aspiration of bone marrow sample for diagnosis15$1,033$69
Biopsy of bone marrow11$841$65

2022: 12 services

Original Medicare services billed in 2022
Return visit (30+ min)410$100,873$82
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes107$75,464$93
Long return visit (40+ min)139$34,078$127
Short return visit (20+ min)196$16,555$54
Initial hospital care with moderate level of medical decision making at least 75 minutes56$14,067$172
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes40$7,079$65
New patient visit (60+ min)28$3,963$142
New patient visit (45+ min)36$3,889$108
Biopsy of bone marrow39$2,848$62
Hospital discharge day management, more than 30 minutes11$2,606$97
Biopsy of bone marrow14$1,040$65
Biopsy and aspiration of bone marrow sample for diagnosis13$952$73

2021: 12 services

Original Medicare services billed in 2021
Return visit (30+ min)393$106,444$83
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes116$58,105$93
Long return visit (40+ min)123$31,605$128
Short return visit (20+ min)266$27,824$54
Initial hospital care with moderate level of medical decision making at least 75 minutes62$14,812$181
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes54$6,251$65
Mechanical separation of red blood cells from blood11$4,800$94
New patient visit (45+ min)37$4,102$111
New patient visit (60+ min)23$3,832$167
Biopsy of bone marrow53$3,431$61
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes16$1,961$123
Biopsy of bone marrow15$1,037$65

2020: 12 services

Original Medicare services billed in 2020
Return visit (30+ min)431$86,520$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes113$68,804$96
Long return visit (40+ min)129$28,098$99
Short return visit (20+ min)229$24,791$45
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes66$9,140$67
Initial hospital care with moderate level of medical decision making at least 75 minutes27$7,938$180
New patient visit (60+ min)43$6,077$141
New patient visit (45+ min)44$4,822$110
Biopsy of bone marrow49$3,607$66
Biopsy of bone marrow17$1,320$66
Short return visit21$729$23
Telephone medical discussion with physician, 11-20 minutes12$527$44

2019: 14 services

Original Medicare services billed in 2019
Return visit (30+ min)430$86,145$65
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes135$67,749$93
Short return visit (20+ min)219$22,841$42
Long return visit (40+ min)102$18,027$99
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes72$14,034$66
Initial hospital care with moderate level of medical decision making at least 75 minutes20$4,923$182
Biopsy of bone marrow60$4,240$64
New patient visit (30+ min)43$2,740$64
New patient visit (45+ min)27$2,716$101
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$1,599$114
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes16$1,445$90
Biopsy of bone marrow14$939$63
New patient visit (15+ min)21$870$41
Short return visit19$574$21

2018: 19 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes110$70,221$93
Return visit (30+ min)379$63,459$69
Return visit (30+ min)235$18,871$50
Short return visit (20+ min)169$18,699$45
Long return visit (40+ min)89$14,117$99
Initial hospital care with moderate level of medical decision making at least 75 minutes43$10,731$173
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes58$9,637$65
New patient visit (60+ min)45$6,561$146
Long return visit (40+ min)63$6,221$80
Short return visit (20+ min)85$5,394$36
New patient visit (60+ min)25$3,153$126
Biopsy of bone marrow47$3,082$64
New patient visit (45+ min)23$2,582$112
Biopsy of bone marrow39$2,473$58
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes21$2,134$89
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes16$1,935$121
Administration of chemotherapy into fluid-filled space between the tissue that cover the brain and spinal cord11$1,436$72
Short return visit34$1,149$23
Short return visit19$495$17

2017: 11 services

Original Medicare services billed in 2017
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes108$67,592$91
Return visit (30+ min)350$64,053$64
Short return visit (20+ min)215$25,213$43
Long return visit (40+ min)115$18,032$94
New patient visit (60+ min)68$9,921$146
Initial hospital care with moderate level of medical decision making at least 75 minutes47$9,752$171
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes42$5,566$63
Biopsy of bone marrow62$4,346$65
Short return visit51$1,835$21
New patient visit (45+ min)16$1,706$107
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes14$1,669$119

2016: 12 services

Original Medicare services billed in 2016
Return visit (30+ min)307$61,920$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes92$48,185$88
Short return visit (20+ min)184$18,635$41
Long return visit (40+ min)64$9,426$92
Initial hospital care with moderate level of medical decision making at least 75 minutes39$7,847$171
New patient visit (60+ min)50$6,799$136
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes39$6,281$62
Biopsy of bone marrow60$4,260$64
New patient visit (45+ min)30$3,011$100
Hospital discharge day management, more than 30 minutes12$1,589$93
Short return visit41$1,443$21
Administration of chemotherapy into fluid-filled space between the tissue that cover the brain and spinal cord12$1,079$67

2015: 11 services

Original Medicare services billed in 2015
Return visit (30+ min)308$56,779$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes80$49,667$88
Short return visit (20+ min)185$16,454$42
Long return visit (40+ min)72$10,351$92
Initial hospital care with moderate level of medical decision making at least 75 minutes25$6,161$171
New patient visit (45+ min)47$4,695$100
Biopsy of bone marrow58$3,817$64
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes26$3,365$61
New patient visit (60+ min)20$2,837$142
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes14$1,614$115
Short return visit36$1,112$21

2014: 9 services

Original Medicare services billed in 2014
Return visit (30+ min)262$59,915$62
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes70$28,963$88
Short return visit (20+ min)129$16,138$41
Long return visit (40+ min)52$8,240$90
Initial hospital care with moderate level of medical decision making at least 75 minutes20$3,577$170
New patient visit (60+ min)20$2,833$142
Biopsy of bone marrow35$2,741$65
New patient visit (45+ min)22$1,974$90
Short return visit35$1,128$21

2013: 10 services

Original Medicare services billed in 2013
Return visit (30+ min)236$48,762$60
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes71$34,393$86
Short return visit (20+ min)101$11,288$39
Long return visit (40+ min)52$8,867$87
Initial hospital care with moderate level of medical decision making at least 75 minutes22$5,514$167
New patient visit (45+ min)51$5,327$104
Biopsy of bone marrow50$3,224$62
New patient visit (60+ min)16$2,100$131
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes16$1,374$60
Short return visit22$780$20

Medicaid work

$1,921 in 2024

Medicaid paid $1,921 for 154 billed services this clinician did in 2024, up to 27 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)154$1,921
Medicaid work by year
2024154127$1,921
2023176425$1,288
2022355721$1,973
20211,009828$4,312
2020772721$1,503
2019501628$1,190
2018480726$578
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)123$1,156
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count20$68
COMPREHENSIVE METABOLIC PANEL17$64
Hospital outpatient clinic visit for assessment and management of a patient16$0

2022

Largest Medicaid services in 2022
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES41$1,175
Return visit (30+ min)79$604
COMPREHENSIVE METABOLIC PANEL29$79
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count45$78
Lactate dehydrogenase (LD), (LDH)28$37
COLLECTION VENOUS BLOOD VENIPUNCTURE30$0
Hospital outpatient clinic visit for assessment and management of a patient103$0

2021

Largest Medicaid services in 2021
Return visit (30+ min)246$3,039
COMPREHENSIVE METABOLIC PANEL191$549
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES41$361
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count169$260
Short return visit (20+ min)16$66
Lactate dehydrogenase (LD), (LDH)74$38
COLLECTION VENOUS BLOOD VENIPUNCTURE50$0
Hospital outpatient clinic visit for assessment and management of a patient222$0

2020

Largest Medicaid services in 2020
Return visit (30+ min)192$897
COMPREHENSIVE METABOLIC PANEL158$274
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count134$226
Hospital outpatient clinic visit for assessment and management of a patient212$49
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES32$46
Lactate dehydrogenase (LD), (LDH)15$11
COLLECTION VENOUS BLOOD VENIPUNCTURE29$0

2019

Largest Medicaid services in 2019
COMPREHENSIVE METABOLIC PANEL77$619
Return visit (30+ min)92$525
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count82$38
Lactate dehydrogenase (LD), (LDH)31$8
COLLECTION VENOUS BLOOD VENIPUNCTURE13$0
Hospital outpatient clinic visit for assessment and management of a patient206$0

2018

Largest Medicaid services in 2018
Return visit (30+ min)90$393
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count125$97
Short return visit (20+ min)17$65
COMPREHENSIVE METABOLIC PANEL79$24
COLLECTION VENOUS BLOOD VENIPUNCTURE38$0
Lactate dehydrogenase (LD), (LDH)17$0
Hospital outpatient clinic visit for assessment and management of a patient114$0

Drugs they prescribed that Part D paid

$9,301,317

Pharmacies billed $9,301,317 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

1,223 generic and 661 brand-name prescriptions · $9,301,317 in drug cost · 115 antibiotic prescriptions to 41 people · 27 antipsychotic prescriptions to people over 65.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Revlimid73$1,477,689$20,242
Jakafi77$1,438,553$18,683
Xpovio43$1,282,121$29,817
Lenalidomide76$1,217,848$16,024
Imbruvica47$723,819$15,400
See all 36 drugs
Every Part D drug this clinician prescribed
Revlimid73$1,477,689$20,242
Jakafi77$1,438,553$18,683
Xpovio43$1,282,121$29,817
Lenalidomide76$1,217,848$16,024
Imbruvica47$723,819$15,400
Brukinsa31$457,057$14,744
Venclexta58$410,821$7,083
Calquence26$399,828$15,378
Ojjaara14$375,754$26,840
Iclusig12$257,383$21,449
Scemblix17$213,075$12,534
Promacta15$194,496$12,966
Xarelto79$89,619$1,134
Eliquis70$52,675$752
Varubi33$42,871$1,299
Posaconazole11$24,630$2,239
Imatinib Mesylate22$8,735$397
Acyclovir340$5,845$17
Atovaquone21$3,886$185
Dexamethasone114$2,379$21
Hydroxyurea102$2,251$22
Entecavir23$1,131$49
Fluconazole22$845$38
Prochlorperazine Maleate53$693$13
Potassium Chloride34$616$18
Ondansetron42$534$13
Sulfamethoxazole-Trimethoprim55$211$4
Allopurinol11$184$17
Olanzapine29$177$6
Warfarin12$162$14
Gabapentin33$141$4
Cephalexin11$122$11
Pantoprazole13$97$7
Amlodipine Besylate11$74$7
Azithromycin15$48$3
Famotidine12$43$4

Year by year

Part D prescribing by year
20241,884185None35%$9,301,317
20231,855195NoneNone$7,214,238
20221,763191NoneNone$8,082,111
20211,981174NoneNone$8,363,329
20201,674171NoneNone$6,446,194
20191,4161562% (29)43%$5,040,960
20181,5081605% (68)31%$3,898,467
20171,2431546% (70)21%$2,195,848
20161,0941306% (69)23%$2,229,373
20158601065% (45)None$1,523,396
20149821167% (73)None$1,185,258
20139801046% (61)19%$1,234,290

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 37 drugs

Part D drugs prescribed in 2023
Revlimid76$1,600,523$21,060
Jakafi73$1,436,927$19,684
Lenalidomide67$1,166,649$17,413
Imbruvica30$510,356$17,012
Venclexta91$407,030$4,473
Calquence25$380,579$15,223
Xpovio12$318,810$26,567
Iclusig12$243,444$20,287
Brukinsa11$154,614$14,056
Promacta11$142,664$12,969
Xarelto112$107,637$961
Posaconazole38$91,349$2,404
Scemblix12$82,952$6,913
Eliquis60$46,065$768
Aminocaproic Acid12$20,004$1,667
Entecavir13$13,450$1,035
Imatinib Mesylate24$7,838$327
Acyclovir283$5,990$21
Potassium Chloride56$2,440$44
Hydroxyurea81$2,425$30
Fluconazole51$2,156$42
Colesevelam11$2,025$184
Dexamethasone90$1,778$20
Dapsone21$1,165$55
Gabapentin49$673$14
Prochlorperazine Maleate48$605$13
Ondansetron18$320$18
Cephalexin12$298$25
Sulfamethoxazole-Trimethoprim44$291$7
Allopurinol20$283$14
Pantoprazole17$281$17
Warfarin14$232$17
Levofloxacin17$216$13
Ondansetron Odt12$213$18
Nystatin12$154$13
Azithromycin21$93$4
Amoxicillin11$12$1

2022: 36 drugs

Part D drugs prescribed in 2022
Revlimid144$3,167,388$21,996
Jakafi59$1,148,892$19,473
Venclexta102$971,142$9,521
Xpovio19$461,689$24,299
Calquence30$451,054$15,035
Promacta19$350,590$18,452
Imbruvica24$312,933$13,039
Iclusig12$225,407$18,784
Ninlaro15$170,755$11,384
Xarelto131$120,977$923
Posaconazole15$63,255$4,217
Eliquis57$38,160$669
Voriconazole13$6,360$489
Imatinib Mesylate17$5,871$345
Acyclovir243$5,521$23
Hydroxyurea93$3,319$36
Fluconazole44$1,928$44
Dexamethasone82$1,913$23
Entecavir11$1,880$171
Dapsone28$1,593$57
Potassium Chloride27$1,141$42
Prochlorperazine Maleate50$764$15
Ondansetron27$444$16
Gabapentin19$367$19
Pantoprazole29$310$11
Amlodipine Besylate20$229$11
Lidocaine Hcl Viscous20$204$10
Allopurinol20$163$8
Sulfamethoxazole-Trimethoprim36$143$4
Nystatin14$120$9
Levofloxacin12$87$7
Folic Acid14$80$6
Azithromycin12$67$6
Warfarin16$54$3
Cephalexin14$51$4
Furosemide11$17$2

2021: 40 drugs

Part D drugs prescribed in 2021
Revlimid144$2,819,480$19,580
Jakafi49$872,494$17,806
Imbruvica52$685,733$13,187
Calquence46$679,576$14,773
Venclexta90$662,822$7,365
Ninlaro36$385,644$10,712
Promacta11$370,863$33,715
Iclusig11$193,515$17,592
Kisqali12$179,552$14,963
Brukinsa12$160,784$13,399
Xarelto151$122,137$809
Inqovi12$98,089$8,174
Procrit16$73,003$4,563
Eliquis44$32,903$748
Deferasirox11$23,277$2,116
Voriconazole20$15,737$787
Imatinib Mesylate15$15,605$1,040
Cyclosporine Modified21$5,886$280
Retacrit12$5,665$472
Acyclovir249$5,289$21
Hydroxyurea118$3,766$32
Dexamethasone103$2,635$26
Potassium Chloride55$2,634$48
Entecavir15$2,557$170
Dapsone35$1,897$54
Fluconazole39$1,583$41
Prochlorperazine Maleate71$984$14
Ondansetron36$552$15
Pantoprazole27$393$15
Letrozole12$374$31
Allopurinol30$316$11
Prednisone17$182$11
Levofloxacin18$169$9
Warfarin17$160$9
Sulfamethoxazole-Trimethoprim39$150$4
Tamsulosin11$147$13
Amlodipine Besylate13$130$10
Gabapentin13$94$7
Cephalexin16$60$4
Folic Acid11$47$4

2020: 35 drugs

Part D drugs prescribed in 2020
Imbruvica133$1,681,135$12,640
Revlimid78$1,349,004$17,295
Jakafi51$770,255$15,103
Pomalyst28$523,334$18,691
Ninlaro32$329,233$10,289
Iclusig12$202,713$16,893
Venclexta31$197,558$6,373
Kisqali12$159,625$13,302
Xarelto116$90,897$784
Procrit13$50,329$3,871
Eliquis49$28,286$577
Imatinib Mesylate11$6,867$624
Entecavir17$5,277$310
Hydroxyurea114$4,806$42
Acyclovir199$4,309$22
Cyclosporine Modified11$2,241$204
Dexamethasone69$1,884$27
Fluconazole34$1,476$43
Vancomycin14$1,401$100
Prochlorperazine Maleate61$767$13
Potassium Chloride49$709$14
Ondansetron30$640$21
Gabapentin21$450$21
Allopurinol29$446$15
Warfarin19$362$19
Clarithromycin11$352$32
Letrozole13$286$22
Pantoprazole17$178$10
Levofloxacin19$175$9
Prednisone20$169$8
Tamsulosin15$155$10
Cephalexin14$86$6
Nystatin11$84$8
Sulfamethoxazole-Trimethoprim40$83$2
Lidocaine Hcl Viscous11$74$7

2019: 29 drugs

Part D drugs prescribed in 2019
Imbruvica124$1,500,962$12,105
Revlimid71$1,155,911$16,280
Jakafi45$599,406$13,320
Pomalyst24$427,753$17,823
Iclusig14$253,388$18,099
Ninlaro20$198,606$9,930
Jadenu17$157,832$9,284
Venclexta14$150,179$10,727
Procrit36$104,432$2,901
Xarelto91$68,039$748
Eliquis54$26,501$491
Hydroxyurea147$5,190$35
Epogen12$4,258$355
Acyclovir118$2,845$24
Dexamethasone66$1,370$21
Potassium Chloride53$981$19
Fluconazole11$636$58
Ondansetron29$594$20
Hydrocodone-Acetaminophen25$562$22
Allopurinol29$466$16
Tamoxifen Citrate12$433$36
Gabapentin28$383$14
Prochlorperazine Maleate34$347$10
Warfarin20$299$15
Cephalexin17$113$7
Azithromycin16$110$7
Pantoprazole12$102$8
Lidocaine Hcl Viscous11$87$8
Prednisone11$86$8

2018: 33 drugs

Part D drugs prescribed in 2018
Imbruvica98$1,136,821$11,600
Revlimid71$1,054,491$14,852
Pomalyst23$378,752$16,467
Ninlaro34$338,527$9,957
Jakafi16$205,794$12,862
Xarelto88$47,995$545
Procrit14$45,071$3,219
Entecavir16$13,346$834
Eliquis23$10,876$473
Hydroxyurea155$4,718$30
Anagrelide16$2,893$181
Acyclovir105$2,219$21
Dexamethasone106$2,168$20
Dutasteride11$1,614$147
Warfarin58$1,401$24
Hydrocodone-Acetaminophen55$1,305$24
Potassium Chloride44$925$21
Ketoconazole16$857$54
Megestrol Acetate13$690$53
Clarithromycin15$655$44
Ondansetron31$634$20
Fluconazole13$544$42
Tamoxifen Citrate14$510$36
Pantoprazole30$439$15
Famciclovir14$435$31
Prochlorperazine Maleate33$384$12
Allopurinol24$290$12
Gabapentin19$231$12
Tamsulosin12$169$14
Cephalexin18$168$9
Lorazepam31$149$5
Azithromycin16$109$7
Omeprazole17$104$6

2017: 24 drugs

Part D drugs prescribed in 2017
Revlimid65$704,785$10,843
Imbruvica46$468,748$10,190
Pomalyst11$161,139$14,649
Xarelto41$17,842$435
Entecavir13$9,768$751
Creon12$8,452$704
Hydroxyurea117$3,592$31
Danazol15$2,813$188
Warfarin113$2,256$20
Acyclovir109$1,692$16
Hydrocodone-Acetaminophen50$1,313$26
Dexamethasone62$1,220$20
Ondansetron41$584$14
Megestrol Acetate15$550$37
Potassium Chloride38$479$13
Famciclovir13$441$34
Ketoconazole11$382$35
Diphenoxylate-Atropine13$267$21
Prochlorperazine Maleate49$245$5
Lorazepam53$186$4
Prednisone13$130$10
Cephalexin16$107$7
Azithromycin18$90$5
Allopurinol11$87$8

2016: 28 drugs

Part D drugs prescribed in 2016
Revlimid78$804,625$10,316
Imbruvica49$505,481$10,316
Pomalyst11$133,864$12,169
Entecavir12$10,255$855
Xarelto19$9,050$476
Creon14$7,514$537
Enoxaparin11$4,330$394
Famciclovir13$3,193$246
Hydrocodone-Acetaminophen60$2,034$34
Warfarin140$2,011$14
Acyclovir89$1,817$20
Hydroxyurea84$1,611$19
Fluconazole30$1,407$47
Dexamethasone34$797$23
Ondansetron26$483$19
Megestrol Acetate13$388$30
Potassium Chloride16$323$20
Nystatin11$251$23
Levofloxacin21$238$11
Prednisone24$230$10
Metronidazole13$190$15
Gabapentin14$186$13
Lorazepam32$179$6
Azithromycin17$169$10
Prochlorperazine Maleate24$120$5
Pantoprazole19$114$6
Cephalexin11$112$10
Omeprazole11$75$7

2015: 23 drugs

Part D drugs prescribed in 2015
Revlimid73$697,429$9,554
Imbruvica22$206,711$9,396
Pomalyst12$143,865$11,989
Promacta12$116,174$9,681
Gleevec12$115,796$9,650
Enoxaparin22$11,915$542
Xarelto12$3,902$325
Hydroxyurea75$1,975$26
Warfarin113$1,887$17
Exemestane11$1,882$171
Hydrocodone-Acetaminophen40$953$24
Acyclovir55$827$15
Dexamethasone46$744$16
Nystatin29$648$22
Potassium Chloride21$509$24
Megestrol Acetate12$315$26
Gabapentin20$266$13
Levothyroxine12$259$22
Omeprazole21$237$11
Levofloxacin17$196$12
Prednisone18$127$7
Lorazepam19$103$5
Azithromycin11$82$7

2014: 20 drugs

Part D drugs prescribed in 2014
Revlimid102$943,413$9,249
Enoxaparin13$12,245$942
Hydroxyurea71$1,822$26
Fluconazole21$1,697$81
Acyclovir89$1,665$19
Warfarin136$1,598$12
Exemestane12$1,560$130
Dexamethasone55$846$15
Hydrocodone-Acetaminophen48$783$16
Omeprazole42$477$11
Nystatin19$447$24
Levofloxacin24$439$18
Pantoprazole29$435$15
Ondansetron11$367$33
Prednisone23$197$9
Azithromycin21$167$8
Lorazepam19$147$8
Gabapentin11$120$11
Amitriptyline12$72$6
Amlodipine Besylate14$55$4

2013: 25 drugs

Part D drugs prescribed in 2013
Revlimid103$884,010$8,583
Gleevec20$132,623$6,631
Tasigna11$92,919$8,447
Acyclovir102$2,295$23
Exemestane11$2,164$197
Hydroxyurea57$2,072$36
Warfarin110$1,823$17
Fluconazole31$1,604$52
Ondansetron17$871$51
Dexamethasone64$656$10
Pantoprazole39$517$13
Hydrocodone-Acetaminophen45$448$10
Levofloxacin22$346$16
Omeprazole25$257$10
Methylphenidate11$206$19
Azithromycin17$171$10
Allopurinol19$143$8
Metoprolol18$132$7
Lorazepam19$110$6
Prednisone12$98$8
Simvastatin12$91$8
Prochlorperazine Maleate11$87$8
Amlodipine Besylate15$77$5
Atenolol12$48$4
Amitriptyline13$23$2

Money from drug and device companies

$164,984 in 2025

Industry payments by year
202552349$144,068$164,984
20241461$46,011$56,386
20231258$53,083$59,789
202212123$132,655$153,920
20211166$71,378$79,547
20201426$18,636$19,881
201923100$41,320$49,418

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Janssen BiotechRybrevant$35,383
49 payments
  • Meals for Darzalex · 2025-11-12 · $54
  • Travel for Rybrevant · 2025-11-05 · $226
  • Meals for Erleada · 2025-10-23 · $36
  • Paid to speak or teach for Rybrevant · 2025-10-23 · $2,860
  • Meals for Rybrevant · 2025-10-22 · $108
  • Paid to speak or teach for Rybrevant · 2025-10-17 · $880
  • Paid to speak or teach for Rybrevant · 2025-10-16 · $3,300
  • Travel for Rybrevant · 2025-10-16 · $234
  • Meals for Darzalex · 2025-10-14 · $48
  • Meals for Rybrevant · 2025-10-09 · $116
  • Meals for Darzalex · 2025-09-04 · $34
  • Paid to speak or teach for Rybrevant · 2025-08-21 · $880
  • Meals for Carvykti · 2025-08-18 · $33
  • Paid to speak or teach for Rybrevant · 2025-08-15 · $3,300
  • Travel for Rybrevant · 2025-08-15 · $50
  • Travel for Rybrevant · 2025-08-15 · $902
  • Travel for Rybrevant · 2025-08-14 · $369
  • Meals for Rybrevant · 2025-08-13 · $121
  • Travel for Rybrevant · 2025-08-11 · $6
  • Paid to speak or teach for Rybrevant · 2025-08-08 · $550
  • Paid to speak or teach for Rybrevant · 2025-08-01 · $2,860
  • Meals for Rybrevant · 2025-07-30 · $122
  • Paid to speak or teach for Rybrevant · 2025-07-29 · $2,860
  • Meals for Rybrevant · 2025-07-24 · $110
  • Travel for Rybrevant · 2025-07-12 · $99
  • Travel for Rybrevant · 2025-07-12 · $115
  • Meals for Rybrevant · 2025-07-12 · $48
  • Paid to speak or teach for Rybrevant · 2025-07-02 · $880
  • Paid to speak or teach for Rybrevant · 2025-07-02 · $1,650
  • Paid to speak or teach for Rybrevant · 2025-07-02 · $3,300
  • Meals for Rybrevant · 2025-06-26 · $27
  • Meals for Rybrevant · 2025-06-26 · $140
  • Meals for Darzalex · 2025-06-25 · $34
  • Travel for Rybrevant · 2025-06-24 · $708
  • Meals for Rybrevant · 2025-06-04 · $26
  • Travel for Rybrevant · 2025-06-02 · $317
  • Meals for Carvykti · 2025-05-20 · $31
  • Meals for Darzalex · 2025-05-14 · $25
  • Meals for Darzalex · 2025-04-17 · $15
  • Travel for Rybrevant · 2025-04-12 · $25
  • Travel for Rybrevant · 2025-04-12 · $83
  • Paid to speak or teach for Rybrevant · 2025-04-08 · $2,860
  • Meals for Rybrevant · 2025-04-03 · $145
  • Paid to speak or teach for Rybrevant · 2025-03-21 · $2,860
  • Meals for Rybrevant · 2025-03-20 · $129
  • Meals for Darzalex · 2025-03-12 · $18
  • Paid to speak or teach for Rybrevant · 2025-02-21 · $1,100
  • Paid to speak or teach for Rybrevant · 2025-02-20 · $660
  • Meals for Darzalex · 2025-02-13 · $31
AbbvieVenclexta$33,806
36 payments
  • Paid to speak or teach for Venclexta · 2025-12-18 · $3,000
  • Paid to speak or teach for Epkinly · 2025-12-18 · $3,000
  • Travel for Epkinly · 2025-12-11 · $164
  • Meals for Epkinly · 2025-12-11 · $41
  • Meals for Venclexta · 2025-12-04 · $125
  • Travel for Venclexta · 2025-12-04 · $251
  • Meals for Venclexta · 2025-11-26 · $0
  • Meals for Epkinly · 2025-11-25 · $25
  • Meals for Venclexta · 2025-11-20 · $19
  • Consulting for Venclexta · 2025-10-10 · $2,100
  • Consulting for Epkinly · 2025-10-01 · $3,600
  • Travel for Epkinly · 2025-10-01 · $275
  • Travel for Epkinly · 2025-10-01 · $779
  • Travel for Epkinly · 2025-10-01 · $250
  • Paid to speak or teach for Venclexta · 2025-09-18 · $3,000
  • Travel for Venclexta · 2025-09-10 · $29
  • Meals for Venclexta · 2025-09-10 · $125
  • Meals for Epkinly · 2025-09-05 · $15
  • Meals for Epkinly · 2025-09-05 · $115
  • Consulting for Venclexta · 2025-08-22 · $1,200
  • Paid to speak or teach for Venclexta · 2025-07-24 · $3,000
  • Travel for Venclexta · 2025-07-14 · $22
  • Travel for Venclexta · 2025-07-14 · $19
  • Meals for Venclexta · 2025-07-14 · $149
  • Consulting for Venclexta · 2025-07-10 · $600
  • Meals for Venclexta · 2025-07-03 · $15
  • Meals for Imbruvica · 2025-06-23 · $17
  • Paid to speak or teach for Venclexta · 2025-05-16 · $4,200
  • Meals for Venclexta · 2025-04-30 · $122
  • Travel for Venclexta · 2025-04-30 · $978
  • Paid to speak or teach · 2025-04-18 · $3,000
  • Travel · 2025-03-21 · $219
  • Meals · 2025-03-21 · $28
  • Consulting for Venclexta · 2025-03-18 · $600
  • Consulting for Venclexta · 2025-02-18 · $2,700
  • Meals for Imbruvica · 2025-01-23 · $22
Karyopharm TherapeuticsXpovio$26,808
19 payments
  • Honoraria for Xpovio · 2025-12-10 · $1,550
  • Honoraria for Xpovio · 2025-10-30 · $3,875
  • Meals for Xpovio · 2025-10-30 · $123
  • Meals for Xpovio · 2025-07-23 · $96
  • Honoraria for Xpovio · 2025-06-17 · $3,875
  • Travel for Xpovio · 2025-06-17 · $218
  • Meals for Xpovio · 2025-06-17 · $119
  • Honoraria for Xpovio · 2025-05-14 · $3,875
  • Travel for Xpovio · 2025-05-14 · $117
  • Meals for Xpovio · 2025-05-14 · $120
  • Honoraria for Xpovio · 2025-04-29 · $775
  • Honoraria for Xpovio · 2025-04-15 · $3,875
  • Meals for Xpovio · 2025-04-15 · $122
  • Travel for Xpovio · 2025-04-15 · $27
  • Meals for Xpovio · 2025-03-27 · $122
  • Honoraria for Xpovio · 2025-03-27 · $3,875
  • Travel for Xpovio · 2025-03-27 · $20
  • Honoraria for Xpovio · 2025-02-12 · $3,875
  • Meals for Xpovio · 2025-02-12 · $148
Genmab U.S.Epkinly$14,707
20 payments
  • Consulting for Epkinly · 2025-11-08 · $1,950
  • Meals for Epkinly · 2025-11-08 · $41
  • Meals for Epkinly · 2025-11-08 · $102
  • Travel for Epkinly · 2025-11-08 · $22
  • Paid to speak or teach for Epkinly · 2025-10-29 · $600
  • Paid to speak or teach for Epkinly · 2025-09-15 · $3,000
  • Travel for Epkinly · 2025-09-09 · $84
  • Paid to speak or teach for Epkinly · 2025-08-01 · $3,000
  • Meals for Epkinly · 2025-07-31 · $125
  • Meals for Epkinly · 2025-07-01 · $26
  • Consulting for Epkinly · 2025-06-13 · $4,160
  • Meals for Epkinly · 2025-05-17 · $25
  • Travel for Epkinly · 2025-05-17 · $47
  • Meals for Epkinly · 2025-05-17 · $50
  • Meals for Epkinly · 2025-05-17 · $35
  • Travel for Epkinly · 2025-05-17 · $68
  • Travel for Epkinly · 2025-05-16 · $273
  • Travel for Epkinly · 2025-05-16 · $71
  • Travel for Epkinly · 2025-05-16 · $989
  • Travel for Epkinly · 2025-05-16 · $38
IncyteMonjuvi$14,048
22 payments
  • Meals for Zynyz · 2025-11-17 · $25
  • Paid to speak or teach for Monjuvi · 2025-10-29 · $2,200
  • Meals for Monjuvi · 2025-10-23 · $124
  • Travel for Monjuvi · 2025-10-23 · $13
  • Paid to speak or teach for Monjuvi · 2025-09-24 · $2,200
  • Meals for Monjuvi · 2025-09-18 · $74
  • Travel for Monjuvi · 2025-09-18 · $198
  • Meals for Monjuvi · 2025-08-14 · $25
  • Meals for Jakafi · 2025-08-12 · $27
  • Paid to speak or teach for Monjuvi · 2025-07-17 · $5,775
  • Meals for Monjuvi · 2025-07-09 · $14
  • Meals for Monjuvi · 2025-06-28 · $30
  • Meals for Monjuvi · 2025-06-28 · $30
  • Meals for Monjuvi · 2025-06-28 · $60
  • Travel for Monjuvi · 2025-06-28 · $304
  • Meals for Monjuvi · 2025-06-28 · $60
  • Travel for Monjuvi · 2025-06-28 · $108
  • Travel for Monjuvi · 2025-06-28 · $1,371
  • Meals for Monjuvi · 2025-06-27 · $13
  • Paid to speak or teach for Monjuvi · 2025-05-30 · $275
  • Consulting · 2025-04-28 · $1,100
  • Meals for Monjuvi · 2025-01-13 · $23
Novartis PharmaceuticalsKymriah$13,115
11 payments
  • Meals for Lutathera · 2025-07-29 · $34
  • Consulting for Kymriah · 2025-07-16 · $4,200
  • Consulting · 2025-06-17 · $2,100
  • Meals for Kymriah · 2025-05-01 · $39
  • Meals for Kymriah · 2025-03-29 · $102
  • Meals for Kymriah · 2025-03-29 · $76
  • Consulting for Kymriah · 2025-03-29 · $5,500
  • Travel for Kymriah · 2025-03-29 · $163
  • Travel for Kymriah · 2025-03-29 · $134
  • Travel for Kymriah · 2025-03-29 · $734
  • Meals for Kisqali · 2025-01-29 · $33
See all 342 published payments
Every published payment
Syndax PharmaceuticalsPaid to speak or teach · 2025-12-24Revuforj$3,128
Legend Biotech USAMeals · 2025-12-22Carvykti$24
Syndax PharmaceuticalsMeals · 2025-12-21None$22
E.R. Squibb & Sons L.L.C.Meals · 2025-12-18Reblozyl$2
E.R. Squibb & Sons L.L.C.Meals · 2025-12-18Reblozyl$30
AbbviePaid to speak or teach · 2025-12-18Venclexta$3,000
AbbviePaid to speak or teach · 2025-12-18Epkinly$3,000
Syndax PharmaceuticalsPaid to speak or teach · 2025-12-18Revuforj$1,043
BeOne Medicines USAMeals · 2025-12-17Brukinsa$24
AbbvieTravel · 2025-12-11Epkinly$164
AbbvieMeals · 2025-12-11Epkinly$41
AstraZeneca Pharmaceuticals LPMeals · 2025-12-11Tagrisso$29
Karyopharm TherapeuticsHonoraria · 2025-12-10Xpovio$1,550
Syndax PharmaceuticalsMeals · 2025-12-09Revuforj$148
Kite PharmaMeals · 2025-12-08Yescarta$26
E.R. Squibb & Sons L.L.C.Meals · 2025-12-04Opdivo$33
AbbvieMeals · 2025-12-04Venclexta$125
AbbvieTravel · 2025-12-04Venclexta$251
Takeda Pharmaceuticals U.S.A.Meals · 2025-12-03Ninlaro$2
Takeda Pharmaceuticals U.S.A.Meals · 2025-12-03Iclusig$22
PfizerMeals · 2025-12-03Ibrance$35
Jazz PharmaceuticalsMeals · 2025-12-02Zepzelca$37
Agios PharmaceuticalsMeals · 2025-12-01Pyrukynd$24
AbbvieMeals · 2025-11-26Venclexta$0
AbbvieMeals · 2025-11-25Epkinly$25
AbbvieMeals · 2025-11-20Venclexta$19
GenzymeMeals · 2025-11-19Sarclisa$26
Array BiopharmaMeals · 2025-11-18Braftovi$24
IncyteMeals · 2025-11-17Zynyz$25
Merck Sharp & DohmeMeals · 2025-11-13Keytruda$32
Janssen BiotechMeals · 2025-11-12Darzalex$54
Takeda Pharmaceuticals U.S.A.Meals · 2025-11-11Ninlaro$1
Takeda Pharmaceuticals U.S.A.Meals · 2025-11-11Iclusig$21
PfizerMeals · 2025-11-11Xtandi$21
Genmab U.S.Consulting · 2025-11-08Epkinly$1,950
Genmab U.S.Meals · 2025-11-08Epkinly$41
Genmab U.S.Meals · 2025-11-08Epkinly$102
Genmab U.S.Travel · 2025-11-08Epkinly$22
Merck Sharp & DohmeMeals · 2025-11-06Keytruda$30
Janssen BiotechTravel · 2025-11-05Rybrevant$226
E.R. Squibb & Sons L.L.C.Meals · 2025-11-05Opdivo$32
GlaxoSmithKlineMeals · 2025-11-05Jemperli$33
InvivydMeals · 2025-11-05Pemgarda$21
E.R. Squibb & Sons L.L.C.Meals · 2025-11-04Opdivo$21
SobiMeals · 2025-11-03Vonjo$36
PfizerMeals · 2025-10-30Padcev$35
Karyopharm TherapeuticsHonoraria · 2025-10-30Xpovio$3,875
Karyopharm TherapeuticsMeals · 2025-10-30Xpovio$123
Takeda Pharmaceuticals U.S.A.Meals · 2025-10-29Ninlaro$2
Takeda Pharmaceuticals U.S.A.Meals · 2025-10-29Iclusig$31
IncytePaid to speak or teach · 2025-10-29Monjuvi$2,200
Genmab U.S.Paid to speak or teach · 2025-10-29Epkinly$600
Merck Sharp & DohmeMeals · 2025-10-27Keytruda$25
Tempus AIMeals · 2025-10-27Xt Cdx$18
Janssen BiotechMeals · 2025-10-23Erleada$36
Janssen BiotechPaid to speak or teach · 2025-10-23Rybrevant$2,860
AstraZeneca Pharmaceuticals LPMeals · 2025-10-23Enhertu$22
IncyteMeals · 2025-10-23Monjuvi$124
IncyteTravel · 2025-10-23Monjuvi$13
Janssen BiotechMeals · 2025-10-22Rybrevant$108
Array BiopharmaMeals · 2025-10-21Lorbrena$36
Merck Sharp & DohmeMeals · 2025-10-20Keytruda$30
Janssen BiotechPaid to speak or teach · 2025-10-17Rybrevant$880
Janssen BiotechPaid to speak or teach · 2025-10-16Rybrevant$3,300
Janssen BiotechTravel · 2025-10-16Rybrevant$234
Ipsen BiopharmaceuticalsMeals · 2025-10-16Onivyde$35
Janssen BiotechMeals · 2025-10-14Darzalex$48
CelgeneMeals · 2025-10-10Reblozyl$1
CelgeneMeals · 2025-10-10Reblozyl$31
AbbvieConsulting · 2025-10-10Venclexta$2,100
Janssen BiotechMeals · 2025-10-09Rybrevant$116
EMD SeronoMeals · 2025-10-08None$22
Gilead SciencesMeals · 2025-10-07Trodelvy$25
E.R. Squibb & Sons L.L.C.Meals · 2025-10-06Opdivo$18
AbbvieConsulting · 2025-10-01Epkinly$3,600
AbbvieTravel · 2025-10-01Epkinly$275
AbbvieTravel · 2025-10-01Epkinly$779
AbbvieTravel · 2025-10-01Epkinly$250
Boehringer Ingelheim PharmaceuticalsMeals · 2025-10-01None$24
EisaiMeals · 2025-09-29Lenvima$24
Deciphera PharmaceuticalsMeals · 2025-09-25Qinlock$22
IncytePaid to speak or teach · 2025-09-24Monjuvi$2,200
GenzymeMeals · 2025-09-22Wayrilz$38
AbbviePaid to speak or teach · 2025-09-18Venclexta$3,000
IncyteMeals · 2025-09-18Monjuvi$74
IncyteTravel · 2025-09-18Monjuvi$198
BeOne Medicines USAMeals · 2025-09-17Brukinsa$24
Kite PharmaMeals · 2025-09-17Yescarta$30
AstraZeneca Pharmaceuticals LPMeals · 2025-09-15Imfinzi$23
Genmab U.S.Paid to speak or teach · 2025-09-15Epkinly$3,000
Fennec PharmaceuticalsMeals · 2025-09-15Fyarro$25
Takeda Pharmaceuticals U.S.A.Meals · 2025-09-12Fruzaqla$22
E.R. Squibb & Sons L.L.C.Consulting · 2025-09-11None$575
CelgeneMeals · 2025-09-11Reblozyl$22
AbbvieTravel · 2025-09-10Venclexta$29
AbbvieMeals · 2025-09-10Venclexta$125
Alexion PharmaceuticalsMeals · 2025-09-10Ultomiris$28
Takeda Pharmaceuticals U.S.A.Meals · 2025-09-10Ninlaro$1
Takeda Pharmaceuticals U.S.A.Meals · 2025-09-10Iclusig$30
Genmab U.S.Travel · 2025-09-09Epkinly$84
E.R. Squibb & Sons L.L.C.Meals · 2025-09-08Opdivo$20
AbbvieMeals · 2025-09-05Epkinly$15
AbbvieMeals · 2025-09-05Epkinly$115
Janssen BiotechMeals · 2025-09-04Darzalex$34
Tempus AIMeals · 2025-09-03Xt Cdx$16
InvivydConsulting · 2025-08-29Pemgarda$2,818
E.R. Squibb & Sons L.L.C.Meals · 2025-08-27Opdivo$23
Adc Therapeutics AmericaMeals · 2025-08-27Zynlonta$22
Jazz PharmaceuticalsMeals · 2025-08-26Zepzelca$35
CelgeneMeals · 2025-08-25Reblozyl$26
E.R. Squibb & Sons L.L.C.Consulting · 2025-08-22None$4,025
AbbvieConsulting · 2025-08-22Venclexta$1,200
AstraZeneca Pharmaceuticals LPMeals · 2025-08-22Imfinzi$28
Janssen BiotechPaid to speak or teach · 2025-08-21Rybrevant$880
Takeda Pharmaceuticals U.S.A.Meals · 2025-08-21Iclusig$27
Syndax PharmaceuticalsMeals · 2025-08-20None$21
Array BiopharmaMeals · 2025-08-19Braftovi$32
Janssen PharmaceuticalsEducation · 2025-08-18None$8
Janssen PharmaceuticalsEducation · 2025-08-18None$16
Janssen BiotechMeals · 2025-08-18Carvykti$33
Janssen BiotechPaid to speak or teach · 2025-08-15Rybrevant$3,300
Janssen BiotechTravel · 2025-08-15Rybrevant$50
Janssen BiotechTravel · 2025-08-15Rybrevant$902
Janssen BiotechTravel · 2025-08-14Rybrevant$369
IncyteMeals · 2025-08-14Monjuvi$25
Janssen BiotechMeals · 2025-08-13Rybrevant$121
IncyteMeals · 2025-08-12Jakafi$27
Janssen BiotechTravel · 2025-08-11Rybrevant$6
Janssen BiotechPaid to speak or teach · 2025-08-08Rybrevant$550
AstraZeneca Pharmaceuticals LPMeals · 2025-08-05Lynparza$26
Daiichi SankyoMeals · 2025-08-04Datroway$28
Janssen BiotechPaid to speak or teach · 2025-08-01Rybrevant$2,860
Genmab U.S.Paid to speak or teach · 2025-08-01Epkinly$3,000
Genmab U.S.Meals · 2025-07-31Epkinly$125
Iovance BiotherapeuticsMeals · 2025-07-31Amtagvi$23
Janssen BiotechMeals · 2025-07-30Rybrevant$122
Merck Sharp & DohmeMeals · 2025-07-30Keytruda$26
Janssen BiotechPaid to speak or teach · 2025-07-29Rybrevant$2,860
Novartis PharmaceuticalsMeals · 2025-07-29Lutathera$34
AstraZeneca Pharmaceuticals LPMeals · 2025-07-28Tagrisso$31
Takeda Pharmaceuticals U.S.A.Meals · 2025-07-25Ninlaro$1
Takeda Pharmaceuticals U.S.A.Meals · 2025-07-25Iclusig$4
Takeda Pharmaceuticals U.S.A.Meals · 2025-07-25Iclusig$21
Janssen BiotechMeals · 2025-07-24Rybrevant$110
AbbviePaid to speak or teach · 2025-07-24Venclexta$3,000
Merck Sharp & DohmeMeals · 2025-07-24Keytruda$30
Karyopharm TherapeuticsMeals · 2025-07-23Xpovio$96
AstraZeneca Pharmaceuticals LPMeals · 2025-07-22Imfinzi$22
Array BiopharmaMeals · 2025-07-22Lorbrena$25
IncytePaid to speak or teach · 2025-07-17Monjuvi$5,775
Novartis PharmaceuticalsConsulting · 2025-07-16Kymriah$4,200
Array BiopharmaMeals · 2025-07-16Lorbrena$26
PfizerMeals · 2025-07-16Xtandi$19
AbbvieTravel · 2025-07-14Venclexta$22
AbbvieTravel · 2025-07-14Venclexta$19
AbbvieMeals · 2025-07-14Venclexta$149
Janssen BiotechTravel · 2025-07-12Rybrevant$99
Janssen BiotechTravel · 2025-07-12Rybrevant$115
Janssen BiotechMeals · 2025-07-12Rybrevant$48
AbbvieConsulting · 2025-07-10Venclexta$600
Merck Sharp & DohmeMeals · 2025-07-10Keytruda$28
IncyteMeals · 2025-07-09Monjuvi$14
Iovance BiotherapeuticsMeals · 2025-07-09Amtagvi$29
Rigel PharmaceuticalsMeals · 2025-07-08Tavalisse$23
E.R. Squibb & Sons L.L.C.Meals · 2025-07-07Opdivo$30
AbbvieMeals · 2025-07-03Venclexta$15
Janssen BiotechPaid to speak or teach · 2025-07-02Rybrevant$880
Janssen BiotechPaid to speak or teach · 2025-07-02Rybrevant$1,650
Janssen BiotechPaid to speak or teach · 2025-07-02Rybrevant$3,300
Merck Sharp & DohmeMeals · 2025-07-02Keytruda$19
Genmab U.S.Meals · 2025-07-01Epkinly$26
CelgeneMeals · 2025-06-30Reblozyl$1
CelgeneMeals · 2025-06-30Reblozyl$30
IncyteMeals · 2025-06-28Monjuvi$30
IncyteMeals · 2025-06-28Monjuvi$30
IncyteMeals · 2025-06-28Monjuvi$60
IncyteTravel · 2025-06-28Monjuvi$304
IncyteMeals · 2025-06-28Monjuvi$60
IncyteTravel · 2025-06-28Monjuvi$108
IncyteTravel · 2025-06-28Monjuvi$1,371
IncyteMeals · 2025-06-27Monjuvi$13
Janssen BiotechMeals · 2025-06-26Rybrevant$27
Janssen BiotechMeals · 2025-06-26Rybrevant$140
Integra LifeSciencesMeals · 2025-06-26Omnigraft$45
Janssen BiotechMeals · 2025-06-25Darzalex$34
Boehringer Ingelheim PharmaceuticalsMeals · 2025-06-25None$27
Janssen BiotechTravel · 2025-06-24Rybrevant$708
AbbvieMeals · 2025-06-23Imbruvica$17
SpringWorks TherapeuticsMeals · 2025-06-23Gomekli$28
Lilly USAMeals · 2025-06-19Verzenio$24
EisaiMeals · 2025-06-19Lenvima$24
GlaxoSmithKlineMeals · 2025-06-18Jemperli$32
AstraZeneca Pharmaceuticals LPEducation · 2025-06-18None$23
Novartis PharmaceuticalsConsulting · 2025-06-17None$2,100
Karyopharm TherapeuticsHonoraria · 2025-06-17Xpovio$3,875
Karyopharm TherapeuticsTravel · 2025-06-17Xpovio$218
Karyopharm TherapeuticsMeals · 2025-06-17Xpovio$119
Genmab U.S.Consulting · 2025-06-13Epkinly$4,160
CelgeneMeals · 2025-06-12Reblozyl$27
Merck Sharp & DohmeMeals · 2025-06-10Keytruda$34
Array BiopharmaMeals · 2025-06-09Braftovi$28
CelgeneMeals · 2025-06-06Reblozyl$32
CelgeneMeals · 2025-06-06Reblozyl$1
E.R. Squibb & Sons L.L.C.Meals · 2025-06-05Opdivo$26
E.R. Squibb & Sons L.L.C.Meals · 2025-06-05Opdivo$1
Janssen BiotechMeals · 2025-06-04Rybrevant$26
Takeda Pharmaceuticals U.S.A.Meals · 2025-06-04Fruzaqla$16
Janssen BiotechTravel · 2025-06-02Rybrevant$317
Takeda Pharmaceuticals U.S.A.Meals · 2025-06-02Ninlaro$1
Takeda Pharmaceuticals U.S.A.Meals · 2025-06-02Iclusig$26
IncytePaid to speak or teach · 2025-05-30Monjuvi$275
Astellas Pharma USMeals · 2025-05-29Vyloy$20
Integra LifeSciencesMeals · 2025-05-29Omnigraft$68
E.R. Squibb & Sons L.L.C.Meals · 2025-05-28Opdivo$21
PfizerMeals · 2025-05-28Elrexfio$7
Agios PharmaceuticalsMeals · 2025-05-21Pyrukynd$32
Janssen BiotechMeals · 2025-05-20Carvykti$31
E.R. Squibb & Sons L.L.C.Consulting · 2025-05-19None$575
Genmab U.S.Meals · 2025-05-17Epkinly$25
Genmab U.S.Travel · 2025-05-17Epkinly$47
Genmab U.S.Meals · 2025-05-17Epkinly$50
Genmab U.S.Meals · 2025-05-17Epkinly$35
Genmab U.S.Travel · 2025-05-17Epkinly$68
AbbviePaid to speak or teach · 2025-05-16Venclexta$4,200
Genmab U.S.Travel · 2025-05-16Epkinly$273
Genmab U.S.Travel · 2025-05-16Epkinly$71
Genmab U.S.Travel · 2025-05-16Epkinly$989
Genmab U.S.Travel · 2025-05-16Epkinly$38
PfizerMeals · 2025-05-15Xtandi$16
Janssen BiotechMeals · 2025-05-14Darzalex$25
Karyopharm TherapeuticsHonoraria · 2025-05-14Xpovio$3,875
Karyopharm TherapeuticsTravel · 2025-05-14Xpovio$117
Karyopharm TherapeuticsMeals · 2025-05-14Xpovio$120
PfizerMeals · 2025-05-13Xtandi$21
Gilead SciencesMeals · 2025-05-13Trodelvy$24
Sanofi US ServicesMeals · 2025-05-12None$20
GenzymeMeals · 2025-05-12None$22
Recordati Rare Diseases Inc.Meals · 2025-05-07Enjaymo$23
SpringWorks TherapeuticsMeals · 2025-05-07Ogsiveo$21
Jazz PharmaceuticalsMeals · 2025-05-06Ziihera$29
Kite PharmaConsulting · 2025-05-04Yescarta$9,470
Kite PharmaMeals · 2025-05-04Yescarta$38
Kite PharmaMeals · 2025-05-04Yescarta$53
Kite PharmaMeals · 2025-05-04Yescarta$67
Kite PharmaMeals · 2025-05-03Yescarta$17
Kite PharmaMeals · 2025-05-03Yescarta$28
Kite PharmaMeals · 2025-05-03Yescarta$58
Kite PharmaMeals · 2025-05-03Yescarta$150
Kite PharmaMeals · 2025-05-02Yescarta$127
Kite PharmaTravel · 2025-05-02Yescarta$427
Kite PharmaTravel · 2025-05-02Yescarta$527
Novartis PharmaceuticalsMeals · 2025-05-01Kymriah$39
AbbvieMeals · 2025-04-30Venclexta$122
AbbvieTravel · 2025-04-30Venclexta$978
Karyopharm TherapeuticsHonoraria · 2025-04-29Xpovio$775
IncyteConsulting · 2025-04-28None$1,100
Merck Sharp & DohmeMeals · 2025-04-28Keytruda$31
Iovance BiotherapeuticsMeals · 2025-04-24Amtagvi$26
GlaxoSmithKlineMeals · 2025-04-23Jemperli$25
ExelixisMeals · 2025-04-21Cabometyx$45
AbbviePaid to speak or teach · 2025-04-18None$3,000
Janssen BiotechMeals · 2025-04-17Darzalex$15
Agios PharmaceuticalsMeals · 2025-04-17Pyrukynd$45
E.R. Squibb & Sons L.L.C.Meals · 2025-04-16Opdivo$41
Takeda Pharmaceuticals U.S.A.Meals · 2025-04-16Ninlaro$1
Takeda Pharmaceuticals U.S.A.Meals · 2025-04-16Iclusig$22
Array BiopharmaMeals · 2025-04-15Xalkori$23
Array BiopharmaMeals · 2025-04-15Xalkori$4
Karyopharm TherapeuticsHonoraria · 2025-04-15Xpovio$3,875
Karyopharm TherapeuticsMeals · 2025-04-15Xpovio$122
Karyopharm TherapeuticsTravel · 2025-04-15Xpovio$27
E.R. Squibb & Sons L.L.C.Meals · 2025-04-14Opdivo$1
E.R. Squibb & Sons L.L.C.Meals · 2025-04-14Opdivo$22
E.R. Squibb & Sons L.L.C.Meals · 2025-04-14Opdivo$1
Janssen BiotechTravel · 2025-04-12Rybrevant$25
Janssen BiotechTravel · 2025-04-12Rybrevant$83
Spectrum PharmaceuticalsMeals · 2025-04-09Rolvedon$31
Janssen BiotechPaid to speak or teach · 2025-04-08Rybrevant$2,860
PfizerMeals · 2025-04-07Ibrance$28
Janssen BiotechMeals · 2025-04-03Rybrevant$145
Puma BiotechnologyMeals · 2025-04-03Nerlynx$27
Novartis PharmaceuticalsMeals · 2025-03-29Kymriah$102
Novartis PharmaceuticalsMeals · 2025-03-29Kymriah$76
Novartis PharmaceuticalsConsulting · 2025-03-29Kymriah$5,500
Novartis PharmaceuticalsTravel · 2025-03-29Kymriah$163
Novartis PharmaceuticalsTravel · 2025-03-29Kymriah$134
Novartis PharmaceuticalsTravel · 2025-03-29Kymriah$734
Takeda Pharmaceuticals U.S.A.Meals · 2025-03-28Ninlaro$8
Takeda Pharmaceuticals U.S.A.Meals · 2025-03-28Ninlaro$13
Syndax PharmaceuticalsMeals · 2025-03-27None$26
Karyopharm TherapeuticsMeals · 2025-03-27Xpovio$122
Karyopharm TherapeuticsHonoraria · 2025-03-27Xpovio$3,875
Karyopharm TherapeuticsTravel · 2025-03-27Xpovio$20
BeOne Medicines USAMeals · 2025-03-24Brukinsa$21
Janssen BiotechPaid to speak or teach · 2025-03-21Rybrevant$2,860
AbbvieTravel · 2025-03-21None$219
AbbvieMeals · 2025-03-21None$28
Janssen BiotechMeals · 2025-03-20Rybrevant$129
CelgeneMeals · 2025-03-20Reblozyl$19
Boehringer Ingelheim PharmaceuticalsMeals · 2025-03-19None$34
AbbvieConsulting · 2025-03-18Venclexta$600
Kite PharmaMeals · 2025-03-18Yescarta$6
Kite PharmaMeals · 2025-03-17Yescarta$14
Astellas Pharma USMeals · 2025-03-17Vyloy$21
Janssen BiotechMeals · 2025-03-12Darzalex$18
GlaxoSmithKlineMeals · 2025-03-11Jemperli$30
AstraZeneca Pharmaceuticals LPMeals · 2025-03-10Tagrisso$14
AstraZeneca Pharmaceuticals LPMeals · 2025-03-10Enhertu$35
PharmaEssentia USAMeals · 2025-03-06Besremi$29
Aveo PharmaceuticalsMeals · 2025-03-04Fotivda$29
Daiichi SankyoMeals · 2025-02-27Enhertu$19
Merck Sharp & DohmeMeals · 2025-02-26Keytruda$34
Array BiopharmaMeals · 2025-02-25Braftovi$20
Janssen BiotechPaid to speak or teach · 2025-02-21Rybrevant$1,100
Janssen BiotechPaid to speak or teach · 2025-02-20Rybrevant$660
Array BiopharmaMeals · 2025-02-20Braftovi$26
Daiichi SankyoMeals · 2025-02-19Enhertu$27
AbbvieConsulting · 2025-02-18Venclexta$2,700
Janssen BiotechMeals · 2025-02-13Darzalex$31
AstraZeneca Pharmaceuticals LPMeals · 2025-02-13Imfinzi$27
Kyowa KirinMeals · 2025-02-12Poteligeo$27
Karyopharm TherapeuticsHonoraria · 2025-02-12Xpovio$3,875
Karyopharm TherapeuticsMeals · 2025-02-12Xpovio$148
EisaiMeals · 2025-02-10Lenvima$29
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-05Ninlaro$1
Takeda Pharmaceuticals U.S.A.Meals · 2025-02-05Ninlaro$21
Novartis PharmaceuticalsMeals · 2025-01-29Kisqali$33
Merck Sharp & DohmeMeals · 2025-01-29Keytruda$21
Coherus OncologyMeals · 2025-01-26Loqtorzi$33
AbbvieMeals · 2025-01-23Imbruvica$22
Kite PharmaMeals · 2025-01-22Yescarta$1
Kite PharmaMeals · 2025-01-22Yescarta$8
Kite PharmaMeals · 2025-01-22Yescarta$9
Merck Sharp & DohmeMeals · 2025-01-22Keytruda$33
CelgeneMeals · 2025-01-16Reblozyl$1
CelgeneMeals · 2025-01-16Reblozyl$29
Merck Sharp & DohmeMeals · 2025-01-16Keytruda$18
BeiGene USAMeals · 2025-01-15Brukinsa$24
Array BiopharmaMeals · 2025-01-14Xalkori$22
IncyteMeals · 2025-01-13Monjuvi$23
Jazz PharmaceuticalsMeals · 2025-01-07Ziihera$33
Genentech USAMeals · 2025-01-06Columvi$29
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $56,386

Payments by company in 2024
AbbvieVenclexta$17,955
23 payments
  • Paid to speak or teach for Venclexta · 2024-12-31 · $4,200
  • Paid to speak or teach for Venclexta · 2024-12-24 · $3,000
  • Meals for Venclexta · 2024-12-11 · $122
  • Travel for Venclexta · 2024-12-11 · $973
  • Meals for Venclexta · 2024-12-04 · $125
  • Travel for Venclexta · 2024-12-04 · $690
  • Consulting for Venclexta · 2024-11-08 · $600
  • Consulting for Venclexta · 2024-07-12 · $4,200
  • Travel for Venclexta · 2024-07-12 · $83
  • Meals for Epkinly · 2024-05-14 · $14
  • Meals for Imbruvica · 2024-05-10 · $6
  • Meals for Imbruvica · 2024-05-10 · $10
  • Meals for Epkinly · 2024-05-05 · $113
  • Meals for Venclexta · 2024-04-27 · $69
  • Meals for Venclexta · 2024-04-27 · $89
  • Meals for Venclexta · 2024-04-27 · $27
  • Travel for Venclexta · 2024-04-27 · $84
  • Travel for Venclexta · 2024-04-27 · $500
  • Meals for Venclexta · 2024-04-26 · $85
  • Travel for Venclexta · 2024-04-26 · $318
  • Travel for Venclexta · 2024-04-26 · $177
  • Consulting · 2024-01-23 · $2,400
  • Travel · 2024-01-23 · $70
Novartis PharmaceuticalsKymriah$10,607
13 payments
  • Meals for Kymriah · 2024-12-08 · $129
  • Meals for Scemblix · 2024-12-06 · $146
  • Consulting for Scemblix · 2024-12-06 · $3,038
  • Meals for Scemblix · 2024-11-05 · $55
  • Meals for Scemblix · 2024-10-29 · $6
  • Meals for Kymriah · 2024-03-13 · $74
  • Meals for Kymriah · 2024-02-22 · $10
  • Meals for Kymriah · 2024-02-21 · $11
  • Consulting for Kymriah · 2024-02-21 · $4,025
  • Travel for Kymriah · 2024-02-21 · $241
  • Travel for Kymriah · 2024-02-21 · $1,906
  • Travel for Kymriah · 2024-02-20 · $872
  • Meals for Kymriah · 2024-01-25 · $96
Karyopharm TherapeuticsXpovio$9,052
7 payments
  • Honoraria for Xpovio · 2024-10-16 · $3,875
  • Travel for Xpovio · 2024-10-16 · $235
  • Meals for Xpovio · 2024-10-16 · $122
  • Meals for Xpovio · 2024-07-17 · $12
  • Honoraria for Xpovio · 2024-07-17 · $3,875
  • Travel for Xpovio · 2024-07-17 · $158
  • Honoraria for Xpovio · 2024-01-27 · $775
Takeda Pharmaceuticals U.S.A.Ninlaro$5,586
3 payments
  • Travel for Ninlaro · 2024-03-20 · $1,611
  • Paid to speak or teach for Ninlaro · 2024-03-14 · $3,850
  • Meals for Ninlaro · 2024-03-06 · $125
AstraZeneca Pharmaceuticals LPImfinzi$3,352
2 payments
  • Consulting · 2024-11-07 · $3,015
  • Travel for Imfinzi · 2024-11-04 · $337
E.R. Squibb & Sons L.L.C.None$2,425
2 payments
  • Consulting · 2024-10-11 · $2,300
  • Travel · 2024-09-16 · $125
BeiGene USABrukinsa$2,275
1 payment
  • Consulting for Brukinsa · 2024-05-17 · $2,275
PfizerElrexfio$2,160
4 payments
  • Consulting for Adcetris · 2024-12-16 · $1,000
  • Meals for Elrexfio · 2024-12-08 · $44
  • Meals for Padcev · 2024-06-06 · $116
  • Consulting for Elrexfio · 2024-06-04 · $1,000
AmgenBlincyto$2,058
1 payment
  • Consulting for Blincyto · 2024-01-12 · $2,058
Daiichi SankyoEnhertu$525
1 payment
  • Consulting for Enhertu · 2024-11-02 · $525
ADC Therapeutics AmericaNone$161
1 payment
  • Meals · 2024-12-08 · $161
Janssen BiotechCarvykti$121
1 payment
  • Meals for Carvykti · 2024-09-19 · $121
Progenics PharmaceuticalsPylarify$86
1 payment
  • Meals for Pylarify · 2024-01-30 · $86
CelgeneNone$24
1 payment
  • Meals · 2024-08-14 · $24

2023: $59,789

Payments by company in 2023
Karyopharm TherapeuticsXpovio$25,776
15 payments
  • Meals for Xpovio · 2023-11-15 · $156
  • Travel for Xpovio · 2023-11-15 · $142
  • Honoraria for Xpovio · 2023-11-15 · $3,875
  • Travel for Xpovio · 2023-09-20 · $95
  • Honoraria for Xpovio · 2023-09-20 · $3,875
  • Travel for Xpovio · 2023-08-16 · $220
  • Honoraria for Xpovio · 2023-08-16 · $3,875
  • Meals for Xpovio · 2023-05-31 · $92
  • Travel for Xpovio · 2023-05-31 · $68
  • Honoraria for Xpovio · 2023-05-31 · $3,875
  • Honoraria for Xpovio · 2023-05-17 · $3,875
  • Travel for Xpovio · 2023-05-17 · $99
  • Meals for Xpovio · 2023-05-17 · $104
  • Honoraria for Xpovio · 2023-03-01 · $3,875
  • Honoraria for Xpovio · 2023-01-07 · $1,550
Takeda Pharmaceuticals U.S.A.Ninlaro$15,044
12 payments
  • Paid to speak or teach for Ninlaro · 2023-08-03 · $5,500
  • Paid to speak or teach for Ninlaro · 2023-07-13 · $1,100
  • Travel for Ninlaro · 2023-07-13 · $204
  • Meals for Ninlaro · 2023-07-12 · $123
  • Travel for Ninlaro · 2023-07-12 · $226
  • Paid to speak or teach for Ninlaro · 2023-07-06 · $5,500
  • Travel for Ninlaro · 2023-07-06 · $1,049
  • Meals for Ninlaro · 2023-06-21 · $123
  • Travel for Ninlaro · 2023-06-20 · $243
  • Travel for Ninlaro · 2023-06-19 · $72
  • Travel for Ninlaro · 2023-05-17 · $623
  • Travel for Ninlaro · 2023-04-06 · $282
Gilead SciencesNone$4,011
6 payments
  • Travel · 2023-05-03 · $145
  • Meals · 2023-05-03 · $125
  • Consulting · 2023-05-03 · $3,370
  • Meals · 2023-04-22 · $55
  • Meals · 2023-04-22 · $45
  • Travel · 2023-04-21 · $271
IncyteNone$3,663
5 payments
  • Consulting · 2023-05-25 · $2,818
  • Meals · 2023-05-12 · $8
  • Travel · 2023-05-12 · $106
  • Travel · 2023-04-21 · $685
  • Meals · 2023-04-21 · $45
E.R. Squibb & Sons L.L.C.None$2,964
2 payments
  • Consulting · 2023-10-10 · $1,235
  • Consulting · 2023-05-30 · $1,729
Genmab U.S.Epkinly$2,621
8 payments
  • Travel for Epkinly · 2023-11-16 · $69
  • Travel for Epkinly · 2023-11-16 · $65
  • Paid to speak or teach for Epkinly · 2023-11-16 · $1,600
  • Travel for Epkinly · 2023-11-04 · $503
  • Travel for Epkinly · 2023-11-04 · $304
  • Meals for Epkinly · 2023-11-04 · $15
  • Meals for Epkinly · 2023-11-04 · $50
  • Meals for Epkinly · 2023-11-04 · $15
AmgenBlincyto$2,058
1 payment
  • Consulting for Blincyto · 2023-12-06 · $2,058
Daiichi SankyoNone$1,410
1 payment
  • Consulting · 2023-03-08 · $1,410
Janssen Scientific AffairsImbruvica$1,363
1 payment
  • Consulting for Imbruvica · 2023-10-10 · $1,363
AbbVieVenclexta$845
5 payments
  • Meals for Epkinly · 2023-11-11 · $60
  • Meals for Epkinly · 2023-11-11 · $20
  • Meals for Epkinly · 2023-11-11 · $50
  • Consulting for Venclexta · 2023-10-04 · $600
  • Meals for Venclexta · 2023-01-28 · $115
SeagenAdcetris$19
1 payment
  • Meals for Adcetris · 2023-01-19 · $19
Pharmacyclics LLC An AbbVieImbruvica$15
1 payment
  • Meals for Imbruvica · 2023-05-10 · $15

2022: $153,920

Payments by company in 2022
Karyopharm TherapeuticsXpovio$65,121
36 payments
  • Travel for Xpovio · 2022-11-17 · $196
  • Honoraria for Xpovio · 2022-11-17 · $3,875
  • Meals for Xpovio · 2022-11-17 · $122
  • Honoraria for Xpovio · 2022-11-09 · $3,875
  • Travel for Xpovio · 2022-11-09 · $134
  • Travel for Xpovio · 2022-10-26 · $8
  • Honoraria for Xpovio · 2022-10-26 · $3,875
  • Meals for Xpovio · 2022-10-26 · $87
  • Travel for Xpovio · 2022-10-26 · $6
  • Meals for Xpovio · 2022-08-24 · $20
  • Meals for Xpovio · 2022-08-24 · $5
  • Travel for Xpovio · 2022-08-24 · $774
  • Travel for Xpovio · 2022-08-24 · $473
  • Honoraria for Xpovio · 2022-08-24 · $7,750
  • Travel for Xpovio · 2022-08-24 · $157
  • Honoraria for Xpovio · 2022-06-29 · $5,425
  • Meals for Xpovio · 2022-06-29 · $28
  • Travel for Xpovio · 2022-06-29 · $860
  • Honoraria for Xpovio · 2022-05-19 · $3,875
  • Honoraria for Xpovio · 2022-05-09 · $3,875
  • Meals for Xpovio · 2022-05-09 · $88
  • Honoraria for Xpovio · 2022-05-04 · $3,875
  • Meals for Xpovio · 2022-05-04 · $135
  • Travel for Xpovio · 2022-05-04 · $90
  • Honoraria for Xpovio · 2022-04-25 · $3,875
  • Travel for Xpovio · 2022-04-25 · $83
  • Meals for Xpovio · 2022-04-25 · $22
  • Travel for Xpovio · 2022-03-23 · $638
  • Honoraria for Xpovio · 2022-03-23 · $5,425
  • Meals for Xpovio · 2022-03-23 · $94
  • Meals for Xpovio · 2022-02-09 · $15
  • Honoraria for Xpovio · 2022-02-09 · $3,100
  • Travel for Xpovio · 2022-02-09 · $2,837
  • Honoraria for Xpovio · 2022-02-09 · $7,750
  • Meals for Xpovio · 2022-02-09 · $124
  • Honoraria for Xpovio · 2022-01-29 · $1,550
Takeda Pharmaceuticals U.S.A.Ninlaro$30,246
26 payments
  • Paid to speak or teach for Ninlaro · 2022-12-22 · $3,850
  • Paid to speak or teach for Ninlaro · 2022-12-22 · $2,750
  • Travel for Ninlaro · 2022-12-21 · $841
  • Travel for Ninlaro · 2022-12-21 · $782
  • Meals for Ninlaro · 2022-12-13 · $93
  • Meals for Ninlaro · 2022-12-08 · $63
  • Education · 2022-12-06 · $80
  • Consulting for Ninlaro · 2022-11-16 · $1,650
  • Paid to speak or teach for Ninlaro · 2022-09-15 · $5,500
  • Travel for Ninlaro · 2022-09-12 · $1,544
  • Travel for Ninlaro · 2022-09-01 · $233
  • Meals for Ninlaro · 2022-08-31 · $125
  • Meals for Ninlaro · 2022-08-31 · $49
  • Travel for Ninlaro · 2022-08-31 · $61
  • Travel for Ninlaro · 2022-08-24 · $529
  • Meals for Ninlaro · 2022-08-05 · $102
  • Paid to speak or teach for Ninlaro · 2022-08-04 · $3,850
  • Travel for Ninlaro · 2022-08-03 · $1,202
  • Meals for Ninlaro · 2022-07-27 · $15
  • Paid to speak or teach for Ninlaro · 2022-07-05 · $1,100
  • Paid to speak or teach for Ninlaro · 2022-05-12 · $550
  • Travel for Ninlaro · 2022-04-06 · $783
  • Paid to speak or teach for Ninlaro · 2022-03-31 · $2,750
  • Meals for Ninlaro · 2022-03-16 · $93
  • Paid to speak or teach for Ninlaro · 2022-02-24 · $1,100
  • Paid to speak or teach for Ninlaro · 2022-02-03 · $550
GlaxoSmithKlineBlenrep$28,619
16 payments
  • Paid to speak or teach for Blenrep · 2022-11-03 · $4,800
  • Travel for Blenrep · 2022-09-28 · $120
  • Meals for Blenrep · 2022-09-28 · $22
  • Travel for Blenrep · 2022-09-27 · $1,252
  • Meals for Blenrep · 2022-09-27 · $125
  • Paid to speak or teach for Blenrep · 2022-09-23 · $4,800
  • Travel for Blenrep · 2022-09-14 · $37
  • Paid to speak or teach for Blenrep · 2022-09-14 · $4,800
  • Meals for Blenrep · 2022-09-07 · $19
  • Travel for Blenrep · 2022-09-07 · $1,518
  • Meals for Blenrep · 2022-08-27 · $77
  • Travel for Blenrep · 2022-04-27 · $102
  • Paid to speak or teach for Blenrep · 2022-04-27 · $4,800
  • Meals for Blenrep · 2022-03-31 · $123
  • Consulting for Blenrep · 2022-03-01 · $1,625
  • Paid to speak or teach for Blenrep · 2022-02-16 · $4,400
AbbvieVenclexta$12,069
18 payments
  • Consulting for Venclexta · 2022-10-17 · $4,200
  • Meals for Venclexta · 2022-10-17 · $10
  • Travel for Venclexta · 2022-10-17 · $278
  • Consulting · 2022-10-07 · $4,800
  • Travel · 2022-10-07 · $196
  • Meals for Venclexta · 2022-10-01 · $26
  • Meals for Venclexta · 2022-10-01 · $76
  • Meals for Venclexta · 2022-10-01 · $53
  • Meals for Venclexta · 2022-10-01 · $28
  • Travel for Venclexta · 2022-10-01 · $386
  • Travel for Venclexta · 2022-10-01 · $841
  • Meals for Venclexta · 2022-09-30 · $124
  • Travel for Venclexta · 2022-08-20 · $166
  • Travel for Venclexta · 2022-08-20 · $751
  • Meals for Venclexta · 2022-08-20 · $18
  • Meals for Venclexta · 2022-08-20 · $8
  • Meals for Venclexta · 2022-08-20 · $63
  • Meals for Venclexta · 2022-08-20 · $43
ADC Therapeutics AmericaNone$10,411
8 payments
  • Travel · 2022-10-11 · $79
  • Paid to speak or teach · 2022-10-04 · $3,100
  • Meals · 2022-09-29 · $115
  • Travel · 2022-08-16 · $175
  • Paid to speak or teach · 2022-08-04 · $4,960
  • Meals · 2022-07-21 · $123
  • Paid to speak or teach · 2022-07-12 · $1,240
  • Paid to speak or teach · 2022-04-05 · $620
BeiGene USANone$3,167
6 payments
  • Travel · 2022-12-05 · $101
  • Consulting · 2022-12-05 · $2,600
  • Travel · 2022-11-05 · $141
  • Travel · 2022-11-05 · $146
  • Meals · 2022-11-05 · $86
  • Meals · 2022-11-05 · $93
E.R. Squibb & Sons L.L.C.Abecma$1,660
1 payment
  • Consulting for Abecma · 2022-06-08 · $1,660
PfizerBosulif$1,564
3 payments
  • Honoraria for Bosulif · 2022-07-01 · $1,500
  • Education for Ibrance · 2022-02-25 · $32
  • Education for Ibrance · 2022-02-11 · $32
Janssen BiotechTecvayli$1,004
6 payments
  • Meals for Imbruvica · 2022-08-06 · $6
  • Meals for Darzalex · 2022-06-13 · $5
  • Consulting for Tecvayli · 2022-06-01 · $975
  • Meals for Imbruvica · 2022-04-28 · $5
  • Meals for Imbruvica · 2022-04-07 · $6
  • Meals for Imbruvica · 2022-03-31 · $8
Novartis PharmaceuticalsScemblix$22
1 payment
  • Meals for Scemblix · 2022-04-04 · $22
AmgenLumakras$19
1 payment
  • Meals for Lumakras · 2022-10-28 · $19
Myriad Genetic LaboratoriesPrecisetumor$17
1 payment
  • Meals for Precisetumor · 2022-11-10 · $17

2021: $79,547

Payments by company in 2021
Karyopharm TherapeuticsXpovio$30,313
17 payments
  • Honoraria for Xpovio · 2021-12-15 · $1,850
  • Honoraria for Xpovio · 2021-12-08 · $4,013
  • Travel for Xpovio · 2021-12-08 · $60
  • Meals for Xpovio · 2021-12-08 · $7
  • Honoraria for Xpovio · 2021-10-06 · $5,618
  • Meals for Xpovio · 2021-10-06 · $9
  • Travel for Xpovio · 2021-10-06 · $1,107
  • Honoraria for Xpovio · 2021-06-26 · $1,850
  • Honoraria for Xpovio · 2021-06-23 · $4,013
  • Meals for Xpovio · 2021-06-23 · $8
  • Honoraria for Xpovio · 2021-05-19 · $4,013
  • Travel for Xpovio · 2021-05-19 · $1,033
  • Meals for Xpovio · 2021-05-19 · $10
  • Meals for Xpovio · 2021-04-01 · $12
  • Honoraria for Xpovio · 2021-04-01 · $4,013
  • Travel for Xpovio · 2021-04-01 · $848
  • Honoraria for Xpovio · 2021-03-25 · $1,850
Takeda Pharmaceuticals U.S.A.Ninlaro$26,478
18 payments
  • Paid to speak or teach for Ninlaro · 2021-12-23 · $3,850
  • Paid to speak or teach for Ninlaro · 2021-12-16 · $1,100
  • Meals for Ninlaro · 2021-12-10 · $113
  • Travel for Ninlaro · 2021-12-09 · $693
  • Paid to speak or teach for Ninlaro · 2021-11-29 · $2,750
  • Meals for Ninlaro · 2021-11-22 · $125
  • Travel for Ninlaro · 2021-11-17 · $194
  • Paid to speak or teach for Ninlaro · 2021-10-21 · $2,750
  • Meals for Ninlaro · 2021-10-08 · $125
  • Paid to speak or teach for Ninlaro · 2021-09-29 · $2,750
  • Meals for Ninlaro · 2021-09-16 · $125
  • Travel for Ninlaro · 2021-09-16 · $512
  • Paid to speak or teach for Ninlaro · 2021-08-26 · $5,500
  • Travel for Ninlaro · 2021-08-20 · $787
  • Meals for Ninlaro · 2021-08-06 · $30
  • Travel for Ninlaro · 2021-07-29 · $398
  • Paid to speak or teach for Ninlaro · 2021-05-13 · $1,375
  • Consulting for Exkivity · 2021-04-02 · $3,300
ADC Therapeutics AmericaNone$14,047
15 payments
  • Paid to speak or teach · 2021-12-02 · $1,250
  • Travel · 2021-11-30 · $83
  • Travel · 2021-11-30 · $167
  • Paid to speak or teach · 2021-11-16 · $2,500
  • Paid to speak or teach · 2021-11-12 · $2,500
  • Travel · 2021-11-11 · $826
  • Meals · 2021-11-10 · $121
  • Meals · 2021-11-05 · $122
  • Meals · 2021-11-04 · $8
  • Meals · 2021-11-04 · $34
  • Travel · 2021-11-04 · $193
  • Meals · 2021-11-03 · $122
  • Paid to speak or teach · 2021-11-02 · $2,500
  • Paid to speak or teach · 2021-11-02 · $3,500
  • Meals · 2021-10-21 · $122
IncyteNone$2,153
1 payment
  • Consulting · 2021-10-20 · $2,153
PfizerInlyta$1,847
8 payments
  • Education for Inlyta · 2021-12-14 · $26
  • Education for Inlyta · 2021-11-16 · $8
  • Education for Lorbrena · 2021-11-09 · $12
  • Education for Lorbrena · 2021-11-09 · $16
  • Education for Lorbrena · 2021-11-02 · $16
  • Education for Ibrance · 2021-10-25 · $8
  • Honoraria · 2021-10-07 · $1,750
  • Education for Inlyta · 2021-03-24 · $13
Jazz PharmaceuticalsVyxeos$1,500
1 payment
  • Consulting for Vyxeos · 2021-06-17 · $1,500
E.R. Squibb & Sons L.L.C.None$1,245
1 payment
  • Consulting · 2021-09-28 · $1,245
Adaptive BiotechnologiesClonoseq$1,000
1 payment
  • Consulting for Clonoseq · 2021-08-11 · $1,000
CelgeneOnureg$885
1 payment
  • Consulting for Onureg · 2021-08-05 · $885
Pharmacyclics LLC An AbbVieImbruvica$54
2 payments
  • Meals for Imbruvica · 2021-10-20 · $28
  • Meals for Imbruvica · 2021-05-05 · $26
GlaxoSmithKlineBlenrep$26
1 payment
  • Meals for Blenrep · 2021-02-10 · $26

2020: $19,881

Payments by company in 2020
Karyopharm TherapeuticsXpovio$8,156
4 payments
  • Honoraria for Xpovio · 2020-12-19 · $1,850
  • Honoraria for Xpovio · 2020-09-29 · $2,906
  • Honoraria for Xpovio · 2020-07-20 · $1,850
  • Honoraria for Xpovio · 2020-01-16 · $1,550
Takeda Pharmaceuticals U.S.A.Ninlaro$5,973
6 payments
  • Paid to speak or teach for Ninlaro · 2020-12-16 · $1,100
  • Meals · 2020-03-10 · $24
  • Travel for Ninlaro · 2020-02-20 · $911
  • Paid to speak or teach for Ninlaro · 2020-02-13 · $3,850
  • Meals for Ninlaro · 2020-02-13 · $70
  • Meals · 2020-01-21 · $18
CelgeneInrebic$2,430
2 payments
  • Consulting for Inrebic · 2020-12-18 · $930
  • Consulting · 2020-03-20 · $1,500
BeiGene USABrukinsa$1,650
1 payment
  • Consulting for Brukinsa · 2020-10-15 · $1,650
Rigel PharmaceuticalsTavalisse$1,000
1 payment
  • Paid to speak or teach for Tavalisse · 2020-05-19 · $1,000
BeiGeneBrukinsa$450
1 payment
  • Consulting for Brukinsa · 2020-06-08 · $450
Janssen BiotechDarzalex$43
2 payments
  • Meals for Darzalex · 2020-11-06 · $31
  • Meals for Darzalex · 2020-11-05 · $12
PfizerXalkori$38
3 payments
  • Education for Inlyta · 2020-08-19 · $13
  • Education for Xalkori · 2020-03-09 · $14
  • Education for Lorbrena · 2020-03-09 · $11
AmgenProlia$33
1 payment
  • Meals for Prolia · 2020-01-10 · $33
E.R. Squibb & Sons L.L.C.Opdivo$25
1 payment
  • Education for Opdivo · 2020-07-27 · $25
Daiichi SankyoInjectafer$23
1 payment
  • Meals for Injectafer · 2020-02-20 · $23
AbbVieVenclexta$22
1 payment
  • Meals for Venclexta · 2020-01-06 · $22
Alexion PharmaceuticalsUltomiris$20
1 payment
  • Meals for Ultomiris · 2020-02-26 · $20
Kite PharmaNone$17
1 payment
  • Meals · 2020-11-11 · $17

2019: $49,418

Payments by company in 2019
Takeda Pharmaceuticals U.S.A.Ninlaro$20,158
24 payments
  • Meals · 2019-07-17 · $10
  • Meals · 2019-07-02 · $20
  • Travel for Ninlaro · 2019-06-30 · $782
  • Meals · 2019-06-28 · $1
  • Meals for Ninlaro · 2019-06-26 · $111
  • Paid to speak or teach for Ninlaro · 2019-06-26 · $3,850
  • Travel for Ninlaro · 2019-06-24 · $24
  • Travel for Ninlaro · 2019-06-09 · $264
  • Travel for Ninlaro · 2019-06-08 · $164
  • Meals for Ninlaro · 2019-06-08 · $17
  • Meals for Ninlaro · 2019-06-08 · $35
  • Paid to speak or teach for Ninlaro · 2019-06-08 · $5,500
  • Travel for Ninlaro · 2019-05-30 · $215
  • Travel for Ninlaro · 2019-05-21 · $543
  • Paid to speak or teach for Ninlaro · 2019-04-27 · $4,950
  • Meals for Ninlaro · 2019-04-27 · $155
  • Meals for Ninlaro · 2019-03-27 · $43
  • Meals · 2019-03-06 · $28
  • Paid to speak or teach for Ninlaro · 2019-02-21 · $2,750
  • Travel for Ninlaro · 2019-02-21 · $593
  • Meals for Ninlaro · 2019-02-21 · $76
  • Meals for Ninlaro · 2019-02-14 · $14
  • Meals for Ninlaro · 2019-02-14 · $1
  • Meals for Ninlaro · 2019-01-16 · $13
AstraZeneca Pharmaceuticals LPCalquence$7,551
14 payments
  • Meals for Imfinzi · 2019-12-04 · $44
  • Meals for Imfinzi · 2019-12-04 · $76
  • Consulting for Imfinzi · 2019-10-31 · $2,800
  • Meals for Imfinzi · 2019-10-29 · $131
  • Travel for Imfinzi · 2019-10-29 · $62
  • Consulting for Calquence · 2019-10-24 · $3,330
  • Travel for Calquence · 2019-07-30 · $195
  • Travel for Calquence · 2019-07-30 · $234
  • Meals for Calquence · 2019-07-30 · $134
  • Travel for Calquence · 2019-07-30 · $79
  • Meals for Calquence · 2019-07-30 · $125
  • Travel for Calquence · 2019-07-30 · $324
  • Meals for Tagrisso · 2019-07-27 · $16
  • Meals for Tagrisso · 2019-07-25 · $1
Janssen BiotechImbruvica$5,795
17 payments
  • Meals for Imbruvica · 2019-12-23 · $7
  • Meals for Imbruvica · 2019-12-19 · $8
  • Meals for Darzalex · 2019-12-06 · $17
  • Meals for Erleada · 2019-12-06 · $2
  • Meals for Imbruvica · 2019-12-06 · $5
  • Meals for Erleada · 2019-12-05 · $1
  • Meals for Darzalex · 2019-10-04 · $15
  • Travel for Imbruvica · 2019-08-28 · $73
  • Meals for Imbruvica · 2019-08-28 · $18
  • Consulting for Imbruvica · 2019-07-23 · $3,315
  • Travel for Imbruvica · 2019-07-13 · $1,052
  • Meals for Imbruvica · 2019-07-13 · $30
  • Meals for Imbruvica · 2019-07-13 · $24
  • Meals for Imbruvica · 2019-07-13 · $41
  • Travel for Darzalex · 2019-02-11 · $57
  • Consulting for Darzalex · 2019-01-30 · $1,005
  • Meals for Darzalex · 2019-01-10 · $125
Jazz PharmaceuticalsNone$5,551
8 payments
  • Consulting · 2019-05-01 · $450
  • Consulting · 2019-03-13 · $4,050
  • Meals · 2019-03-02 · $6
  • Travel · 2019-03-02 · $105
  • Travel · 2019-03-02 · $442
  • Travel · 2019-03-02 · $125
  • Travel · 2019-03-02 · $259
  • Meals · 2019-03-02 · $114
AbbVieNone$4,800
1 payment
  • Consulting · 2019-06-11 · $4,800
CelgenePomalyst$4,697
4 payments
  • Travel for Pomalyst · 2019-08-14 · $36
  • Consulting for Pomalyst · 2019-07-24 · $4,520
  • Meals for Pomalyst · 2019-07-12 · $116
  • Meals for Revlimid · 2019-03-14 · $24
Novartis PharmaceuticalsRydapt$226
3 payments
  • Meals for Rydapt · 2019-10-30 · $184
  • Meals for Promacta · 2019-07-16 · $18
  • Meals for Kisqali · 2019-03-28 · $25
Seattle GeneticsAdcetris$94
2 payments
  • Education · 2019-12-05 · $77
  • Meals for Adcetris · 2019-03-01 · $17
ExelixisCabometyx$92
2 payments
  • Meals for Cabometyx · 2019-05-08 · $73
  • Meals for Cabometyx · 2019-04-17 · $19
AmgenKanjinti$85
4 payments
  • Meals for Kanjinti · 2019-12-13 · $31
  • Meals for Neulasta · 2019-06-25 · $16
  • Meals for Nplate · 2019-04-23 · $22
  • Meals for Kyprolis · 2019-04-15 · $16
E.R. Squibb & Sons L.L.C.Opdivo$51
3 payments
  • Meals for Opdivo · 2019-07-30 · $20
  • Meals for Opdivo · 2019-04-04 · $13
  • Meals for Opdivo · 2019-03-07 · $18
PfizerBosulif$50
3 payments
  • Education for Braftovi · 2019-11-04 · $13
  • Meals for Bosulif · 2019-06-27 · $20
  • Meals for Ibrance · 2019-02-21 · $17
Merck Sharp & DohmeKeytruda$43
3 payments
  • Meals for Keytruda · 2019-09-13 · $16
  • Meals for Keytruda · 2019-07-11 · $14
  • Meals for Keytruda · 2019-01-07 · $14
Taiho OncologyLonsurf$42
2 payments
  • Meals for Lonsurf · 2019-05-03 · $18
  • Meals for Lonsurf · 2019-03-26 · $25
Agios PharmaceuticalsTibsovo$34
2 payments
  • Meals for Tibsovo · 2019-06-13 · $19
  • Meals for Tibsovo · 2019-01-19 · $16
TesaroZejula$26
1 payment
  • Meals for Zejula · 2019-05-30 · $26
Astellas Pharma USXospata$22
1 payment
  • Meals for Xospata · 2019-02-19 · $22
Clovis OncologyRubraca$21
1 payment
  • Meals for Rubraca · 2019-04-11 · $21
Bayer HealthCare PharmaceuticalsVitrakvi$19
1 payment
  • Meals for Vitrakvi · 2019-06-06 · $19
EisaiLenvima$18
1 payment
  • Meals for Lenvima · 2019-02-26 · $18
Janssen PharmaceuticalsXarelto$15
1 payment
  • Meals for Xarelto · 2019-05-10 · $15
Boehringer Ingelheim PharmaceuticalsGilotrif$15
1 payment
  • Meals for Gilotrif · 2019-01-10 · $15
Pharmacyclics LLC An AbbVieImbruvica$13
1 payment
  • Meals for Imbruvica · 2019-01-29 · $13

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Novartis Pharmaceuticals Corporation · A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia · 2024Their institution$135,761
ABBVIE INC. · A Phase 3 Multicenter Randomized Open-Label Trial To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With High-Risk Diffuse Large B-Cell Lymphoma · 2024Their institution$104,557
Novartis Pharmaceuticals Corporation · A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia · 2025Their institution$78,236
ABBVIE INC. · M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With High-Risk Diffuse Large B-Cell Lymphoma · 2025Their institution$24,952
Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2022Their institution$21,000
Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2022Their institution$20,300
E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With Or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma · 2022Their institution$19,171
ABBVIE INC. · A Phase 3, Multicenter, Randomized, Open-Label Trial To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With High-Risk Diffuse Large B-Cell Lymphoma · 2024Their institution$17,268
ABBVIE INC. · Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) To Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (Epcore Fl-1) · 2024Their institution$17,268
ABBVIE INC. · Study Assessing Activity of Intravenous (IV) Abbv-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed Or Refractory Multiple Myeloma · 2024Their institution$17,268
ABBVIE INC. · A Phase 3 Multicenter Randomized Open-Label Trial To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With High-Risk Diffuse Large B-Cell Lymphoma · 2025Their institution$15,053
Incyte Corporation · A Phase 2 Study of the Safety, Tolerability, and Efficacy of Incb050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis · 2019Their institution$9,071
Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2020Their institution$7,000
ABBVIE INC. · A Phase 3, Randomized, Open-Label Study To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl) · 2024Their institution$5,666
Celgene Corporation · Celgene - Connect Mds/Aml · 2020Their institution$4,875
E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open Label Trial of Lenalidomidedexamethasone With Or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma · 2019Their institution$3,889
Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2024Their institution$3,885
Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2025Their institution$3,882
Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2024Their institution$3,450
Celgene Corporation · Celgene - Connect Mdsaml · 2019Their institution$3,375
Celgene Corporation · Connect Mds/Aml · 2021Their institution$3,125
Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-50 · 2021Their institution$3,000
Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, Or Mantle Cell Lymphoma · 2023Their institution$2,796
Celgene Corporation · Connect Mds/Aml - Connect Myeloid: the Myelofibrosis (Mf), Myelodysplastic Syndromes (Mds) and Acute Myeloid Leukemia (Aml) Disease Registry: the Purpose of the Connect Myeloid Disease Registry Is To Provide Unique Insights Into Treatment Decisions and Tr · 2023Their institution$2,625
Celgene Corporation · Connect Mds/Aml - Connect Myeloid: the Myelofibrosis (Mf), Myelodysplastic Syndromes (Mds) and Acute Myeloid Leukemia (Aml) Disease Registry: the Purpose of the Connect Myeloid Disease Registry Is To Provide Unique Insights Into Treatment Decisions and Tr · 2022Their institution$2,250
Celgene Corporation · Connect Mm- the Multiple Myeloma Disease Registry (Os002982) · 2019Their institution$2,250
Celgene Corporation · Connect Myeloid: the Myelofibrosis (Mf), Myelodysplastic Syndromes (Mds) and Acute Myeloid Leukemia (Aml) Disease Registry. the Purpose of the Connect Myeloid Disease Registry Is To Provide Unique Insights Into Treatment Decisions and Treatment Patterns As They Relate To Clinical Outcomes of Patients With Myeloid Diseases in Routine Clinical Practice. · 2025Their institution$1,875
Celgene Corporation · Connect Mm- the Multiple Myeloma Disease Registry · 2021Their institution$1,875
Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2023Their institution$1,850
Celgene Corporation · Celgene Connect Myeloid Disease Registry · 2024Their institution$1,500
Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2023Their institution$1,350
Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, Or Mantle Cell Lymphoma(Ca078-P10) (Cc-5013-Nhl-008) · 2019Their institution$1,326
Celgene Corporation · Celgene - Connect Mm · 2020Their institution$1,145
Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-50 · 2022Their institution$910
E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With Or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma · 2020Their institution$900
Celgene Corporation · A Phase 3b Randomized Study of Lenalidomide (Cc-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, Or Mantle Cell Lymphoma(Ca078-P10) · 2020Their institution$864
Celgene Corporation · Celgene - Connect Cll · 2019Their institution$750
Celgene Corporation · Celgene - Connect Mm · 2019Their institution$750
Celgene Corporation · The Purpose of the Connect Myeloid Disease Registry Is To Provide Unique Insights Into Treatment Decisions and Treatment Patterns As They Relate To Clinical Outcomes of Patients With Myeloid Diseases in Routine Clinical Practice. · 2024Their institution$750
Celgene Corporation · Connect Mm- the Multiple Myeloma Disease Registry · 2023Their institution$375
E.R. Squibb & Sons, L.L.C. · Connect Mm the Multiple Myeloma Disease Registry · 2024Their institution$375
Celgene Corporation · Connect Mm- the Multiple Myeloma Disease Registry · 2022Their institution$375
AbbVie Inc. · A Phase 3, Randomized, Open-Label Study To Evaluate Safety and Efficacy of Epcoritamab in Combination With R-Chop Compared To R-Chop in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (Dlbcl) · 2023This clinician$35

Professional record

NPI
1104844174
Licence
MA 223551
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0003X (207RH0003X)
Mailing address
10470 Old Placerville Rd, Sacramento, CA, 95827
NPI first listed
2006-07-18
NPI last updated
2007-07-08

This is when the NPI record was last certified, not a medical board exam.